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Abstract 
More than 90% of the human population is latently infected with the Cytomegalovirus 
(CMV). Infectious virus is not produced during latent infection, but the viral genomes 
remain in infected host cells for years and retain the ability to reactivate upon episodes 
of immune suppression. The murine CMV (MCMV) and the human CMV (HCMV) 
infection share important similarities in terms of pathogenesis and immunity and MCMV 
is one of the best characterised and most commonly used in vivo models of CMV 
infections. The immediate-early genes ie1 and ie3 from MCMV are homologues of ie1 
and ie2 from HCMV. These genes play critical regulatory roles in primary infection and 
in reactivation from latency in both viruses. During viral latency, the immune system is 
weakly, but constantly, stimulated by viral antigens, resulting in an expansion of 
CMV-specific CD8+ T cells, a phenomenon termed Memory Inflation (MI). The large 
fraction of CMV-specific CD8+ T cells is composed of effector memory T cells (TEM), 
and it is assumed that these cells are short-lived, but regularly replenished with antigen 
specific cells from other T cell subsets. 
To define whether expression of the ie1 and ie3 genes during latency is responsible for 
maintenance of MI, the recombinant virus MCMV IE1/3flox was generated by flanking 
the ie1/3 transcriptional unit with loxP sites, which allows the recombination of the 
target sequence by the enzyme Cre recombinase. The virus was tested in a newly 
established in vitro latency model in which the addition of IFNβ reversibly inhibits 
MCMV replication. Upon IFNβ retraction, MCMV WT, but not MCMV IE1/3flox, 
reactivated from cells expressing the Cre recombinase, indicating that Cre excised the 
ie1/3 region in the presence of IFNβ-recruited cellular repressors. To test the system 
in vivo, mice expressing a Tamoxifen (Tam)-inducible Cre recombinase (Cre.ERT2) 
were infected with MCMV IE1/3flox or MCMV WT. In the absence of Tam, non-activated 
Cre.ERT2 did not influence the MI kinetic. The administration of Tam at 4 months post 
infection should have allowed the selective targeting of the loxP sites at times of viral 
latency. Indeed, the percentage of MCMV-specific inflationary CD8+ T cells and the 
relative size of the TEM cell subset were transiently decreased upon Tam administration 
in Cre.ERT2 mice, but not in the parental C57BL/6 strain. However, unexpectedly, 
activated Cre.ERT2 had the same effect in mice infected with MCMV WT, strongly 
arguing that the effects were not due to the targeted recombination of viral genomes. 
This apparent contradiction could be explained by direct toxicity of Cre.ERT2 on the 
proliferating T cells. Analysis of the CD8+ T cell subsets in the spleens of latently 
infected Cre.ERT2 mice for their susceptibility to Cre-mediated toxicity revealed 
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increased apoptosis only in the TEM cell subset, whereas naive T cells and central 
memory T cells (TCM) were not affected. This suggests that the observed reduction of 
TEM cells was not caused by the elimination of cycling naive or TCM cells and 
consequently less recruitment of these cells to the TEM cell subset, because only the 
TEM cells were directly affected by Tam administration to Cre.ERT2 mice. In conclusion, 
the results argue that inflationary CD8+ T cells and TEM cells in general are maintained, 
at least in part, by cyclic TEM cells. 
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Zusammenfassung 
Mehr als 90% der menschlichen Bevölkerung sind latent mit dem Zytomegalievirus 
(eng. Cytomegalovirus (CMV)) infiziert. In dieser Phase der Infektion werden keine 
infektiösen Viren produziert, aber deren Genome lassen sich in infizierten Wirtszellen 
nachweisen. In Folge von Immunsuppressionen kann das Virus reaktivieren. Die 
murine CMV (MCMV) und die menschliche CMV (HCMV) Infektion haben wichtige 
Gemeinsamkeiten in Bezug auf die Pathogenese und Immunität, wobei MCMV eines 
der am besten charakterisierten und meistgenutzten in vivo Modelle der CMV-Infektion 
ist. Die „immediate-early“ Gene ie1 und ie3 von MCMV sind Homologe der Gene ie1 
und ie2 von HCMV. In beiden Viren haben diese Gene kritische regulatorische Rollen 
während der primären Infektion und der Reaktivierung aus der Latenz. Während der 
viralen Latenz wird das Immunsystem zwar nur gering, aber permanent durch virale 
Antigene stimuliert, wodurch es zu einer Expansion von CMV-spezifischen T-Zellen 
kommt, ein Phänomen, welches als „Memory Inflation“ (MI) bezeichnet wird. Der 
Großteil der CMV-spezifischen CD8+ T-Zellen besteht aus Effektorgedächtniszellen 
(TEM-Zellen). Es wird angenommen, dass diese Zellen kurzlebig sind und regelmäßig 
von Antigen-spezifischen Zellen anderer T-Zellsubpopulationen ersetzt werden. 
Um zu klären, ob die Expression der Gene ie1 und ie3 während der Latenz für die 
Aufrechterhaltung der MI verantwortlich ist, wurde das rekombinante Virus MCMV 
IE1/3flox erschaffen. Bei diesem wurde die Transkriptionseinheit von ie1/3 mit 
loxP-Stellen flankiert, was die Rekombination der dazwischenliegenden Sequenz durch 
das Enzym Cre-Rekombinase erlaubt. Das Virus wurde in einem neu entwickelten in 
vitro Latenzmodell getestet, in dem die Zugabe von IFNß die Replikation von MCMV 
reversibel inhibiert. Nach dem IFNβ-Entzug reaktivierte MCMV WT, aber nicht 
MCMV IE1/3flox, in Zellen welche die Cre-Rekombinase exprimieren. Dies weist darauf 
hin, dass das Enzym in Gegenwart von IFNß-rekrutierten zellulären Repressoren die 
Gene ie1 und ie3 entfernen konnte. Um das System in vivo zu testen, wurden C57BL/6 
Mäuse, welche eine Tamoxifen (Tam)-induzierbare Cre-Rekombinase (Cre.ERT2) 
exprimieren, mit MCMV IE1/3flox oder MCMV WT infiziert. In Abwesenheit von Tam, 
hatte die inaktive Cre.ERT2 keinen Einfluss auf die MI. Die Verabreichung von Tam, 
4 Monate nach der Infektion, sollte erreichen, dass das Enzym erst während der viralen 
Latenz Zugriff auf die loxP-Stellen hätte. Tatsächlich wurde der Anteil der inflationären 
MCMV-spezifischen CD8+ T-Zellen und der relative Anteil der TEM-Zellen nach der 
Verabreichung von Tam in Cre.ERT2 Mäusen vorübergehend reduziert. Allerdings 
erzeugte die aktivierte Cre.ERT2 diesen Effekt unerwarteter Weise auch bei Mäusen, 
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welche mit MCMV WT infiziert waren, während dies nicht in normalen 
C57BL/6 Mäusen beobachtet werden konnte. Dies lässt darauf schließen, dass der 
Effekt nicht auf die Rekombination des viralen Genoms zurückzuführen ist. Dieser 
scheinbare Widerspruch könnte durch eine direkte Toxizität der Cre.ERT2 auf 
proliferierende Gedächtnis-T-Zellen erklärt werden. Die Analyse verschiedener 
CD8+ T-Zellsubpopulationen auf deren Anfälligkeit für Cre-vermittelte Toxizität aus der 
Milz latent infizierter Cre.ERT2 Mäuse, ergab einen höheren Anteil von apoptotischen 
Zellen ausschließlich in der TEM-Zellsubpopulation, während die naiven T-Zellen und 
die zentralen Gedächtnis-T-Zellen (TCM) nicht betroffen waren. Dies deutet darauf hin, 
dass die beobachtete Abnahme von TEM-Zellen nicht durch die Eliminierung 
proliferierender naiver T-Zellen oder TCM-Zellen verursacht wurde, was zu weniger 
Rekrutierung dieser Zellen zur TEM-Zellsubpopulation führen würde, weil ausschließlich 
die TEM-Zellen direkt von der Verabreichung von Tam beeinflusst worden zu sein 
schienen. Daraus lässt sich schließen, dass die Anzahl von inflationären 
CD8+ T-Zellen, und TEM-Zellen im Allgemeinen, zumindest teilweise, durch zyklische 
TEM-Zellen aufrechterhalten bleibt. 
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Abbreviations 
7AAD   7-Amino-Actinomycin D 
Ab   antibody 
ACK   Ammonium-Chloride-Potassium 
AIDS   acquired immune deficiency syndrome 
Amp   Ampicillin 
AP-1   activator protein 1 
APC   antigen presenting cell 
BAC   bacterial artificial chromosome 
bp   base pair 
C   capacity 
°C   degree Celsius 
CAM   Chloramphenicol 
CBF1/RBP-Jκ  centromere-binding factor 1/recombination signal binding  
   protein J kappa 
CD   clusters of differentiation 
cDC   conventional dendritic cell 
CIR   corepressor interacting with RBP J 
cm   centimetre 
CMV   Cytomegalovirus 
CO2   carbon dioxide 
CompBeads  compensation beads 
Cre   causes recombination 
Cre-ER  Cre-oestrogen receptor 
CTL   cytotoxic T lymphocyte 
Daxx   death-domain associated protein 
DC   dendritic cell 
dH2O   deionised water 
DMEM   Dulbecco's modified Eagle's medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DOG   deoxy-Galactose 
Dox   Doxycycline 
dpi   days post infection 
EC   endothelial cell 
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E. coli   Escherichia coli 
ER   endoplasmatic reticulum 
ERT/ERT2  modified oestrogen receptor 
EtOH   ethanol 
FACS   fluorescence activated cell sorting 
FCM   flow cytometer 
FCS   fetal calf serum 
g   gravity of earth 
galK   galactokinase 
gB   glycoprotein B 
GOI   gene of interest 
h   hour 
H2O   water 
HBSS   Hank’s balanced salt solution 
HCMV   human Cytomegalovirus 
HDAC   histone deacetylases 
HSV-1   Herpes Simplex Virus 1 
HZI   Helmholtz-Zentrum für Infektionsforschung 
ICCS   intra cellular cytokine staining 
ie   immediate-early 
IFN   Interferon 
IFN-I   type I Interferon 
IFN-II   type II Interferon 
Ig   Immunoglobulin 
IL   Interleukin 
i.p.   intraperitoneal 
Kn   Kanamycin 
kb   kilo base 
kV   kilo Volt 
LB   Luria Bertani 
loxP   locus of crossing over (x), P1 
LSECs   liver sinusoidal endothelial cells 
M   Molar 
MCMV   murine Cytomegalovirus 
MI   memory inflation 
MIE   major immediate-early enhancer 
MIEP   major immediate-early enhancer promoter 
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MEFs   mouse embryonic fibroblasts 
MHC   major histocompatibility complex 
MHC-I   major histocompatibility complex class I 
MHC-II  major histocompatibility complex class II 
µF   micro Farad 
µg   micro grams 
µl   micro litre 
µM   micro Molar 
mg   milligrams 
ml   millilitre 
mM   milli Molar 
min   minute 
MOI   multiplicity of infection 
mRNA   messenger RNA 
msec   millisecond 
N   Nitrogen 
ND10   nuclear domain 10 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
ng   nanograms 
NK cell  natural killer cell 
nm   nanometer 
O2   Oxygen 
OD   optical density 
ORF   open reading frame 
ON   over night 
PBS   phosphate buffered saline 
PCR   Polymerase chain Reaction 
pDC   plasmacytoid dendritic cell 
pfu   plaque forming unit 
p.i.   post infection 
pmol   pikomol 
R   Resistance 
R26   Rosa26 
RAG-1/-2  recombination-activating gene 1/2 
rpm   revolutions per minute 
RPMI   Roswell Park Memorial Institute medium 
RNA   ribonucleic acid 
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RT   room temperature 
rtTA   reverse tetracycline-controlled transactivator 
SD   standard deviation 
sec   second 
SEM   standard error of the mean 
SN   supernatant 
STAT   signal transducer and activator of transcription 
Suppl. DMEM  DMEM supplemented with 10% FCS, 1% Glutamine and 1% 
   Penicillin/Streptomycin 
TAP   transporter associated with antigen processing 
TCM   central memory T cell 
TCR   T cell receptor 
TEM   effector memory T cell 
tetO   operator sequences or tetracycline-responsive elements 
TNF   tumour-necrosis-factor 
U   electric tension 
UV   ultraviolet 
V   Volt 
VSB   virus standard buffer 
WT   wild type 
YY1   Yin Yang 1 
Ω   Ohm 
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1 Introduction 
 
1.1 Herpesvirus 
Cytomegaloviruses (CMVs) are members of the large family Herpesviridae (gr. herpein, 
to creep). These viruses belong to the Herpesvirales which are part of the double 
stranded DNA viruses (according to the International Committee on Taxonomy of 
Viruses (ICTV)). 
According to their replicative cycle and host range, Herpesviridae are classified into 
three subfamilies: alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae. 
Herpesviridae members have in common that they are able to establish a life-long 
latent infection. This means, that viral genomes persist in the organism in the absence 
of infectious viral particles, after the primary infection has been cleared. The remaining 
genomes are silenced in a reversible manner, which may lead to viral recurrence if the 
host immune system becomes weakened and cannot control the virus anymore. 
Herpesvirus infections were identified in almost all vertebrate classes, including 
mammals, birds, reptiles, amphibians or fishes (reviewed in [1]), but also in 
invertebrates, for example in some bivalve species [2]. 
 
All members of the Herpesviridae family are large enveloped viruses, e.g. the human 
CMV (HCMV), a betaherpesvirinae, has a size of 150 – 200 nm. The DNA is packed, 
together with some proteins, in an icosahedral nucleocapsid and the capsid is 
surrounded by a dense proteinaceous matrix: the tegument. This in turn is enveloped 
by a host-derived lipid bi-layer which is decorated with viral glycoproteins (Figure 1) 
(reviewed in [3]). 
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Figure 1 Structure of HCMV virion. 
Herpesvirus virions are composed of three layers. The first inner layer consists of the 
nucleocapsid, which contains the double-stranded viral DNA genome. The capsid is surrounded 
by the tegument. The tegument is enveloped by a host-derived lipid bi-layer which is studded 
with viral glycoproteins. (modified from Streblow et a, [4]) 
 
1.2 Cytomegalovirus 
CMVs belong to the betaherpesvirinae, characterised by slower reproduction than the 
members of the other two subfamilies. The name cytomegalovirus comes from the 
Greek cyto, which means “cell” and megalo, which means “large”. CMVs are strictly 
species-specific, it can only replicate in cells of the host it coevolved with or in cells of a 
closely related species (reviewed in [5]) [6-9]. Due to this species specificity, there are 
many different CMVs, e.g. human CMV, rhesus CMV (rhCMV) or murine CMV (MCMV) 
(reviewed in [1]). 
 
CMVs have very large genomes, e.g. the HCMV genome is ~230 kilo bases (kb) long 
and the MCMV genome is ~235 kb in size [10]. The genome structure differs between 
CMV species, as some have large inverted repeats, whereas others have small repeat 
elements [11]. HCMV has a special structure among the betaherpesvirinae, because its 
genome is composed of the UL and US components, which are flanked with direct and 
inverted repeat elements (reviewed in [3]). Several hundred open reading frames 
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(ORFs) have been identified in the genome of CMVs, but not all of them have been 
demonstrated to encode proteins [12, 13]. 
 
Analysis of the CMV gene expression kinetic has shown that their genes are expressed 
in three overlapping phases: immediate-early (ie), early and late [14, 15]. Immediate-
early genes are the first genes expressed after infection, under the control of strong 
transcriptional enhancers which can be activated by cellular transcription factors 
(reviewed in [16]). The immediate-early proteins interact with cellular anti-viral proteins 
and in the initial phase of infection they are required to activate the expression of early 
and late genes [17-20]. The translation of the ie genes can be suppressed by the 
protein synthesis inhibitor cycloheximid (CHX), which in turn blocks the transcription of 
all other genes, whose expression depends on immediate-early proteins [21]. Early 
genes are involved in DNA replication, immune evasion and viral progression. Late 
genes encode the structural proteins which are necessary to assemble the virions 
(reviewed in [3]). The defining difference between the early and the true late genes is 
the effect of the DNA-polymerase inhibitor phosphonoacetic acid (PAA) on their 
expression. The expression of true late genes depends on DNA replication. Thus, in 
the presence of PAA, only immediate-early and early genes are expressed [21, 22]. 
In the beginning of CMV research gene functions were studied by the use of 
spontaneously mutated viruses or upon chemically or physically induced mutations [23, 
24]. The introduction of the CMV genome into a bacterial artificial chromosome (BAC) 
vector simplified the analysis of the function of individual genes by targeted 
mutagenesis. BAC based mutagenesis allows to maintain the CMV genome in 
Escherichia coli (E. coli) and to modify it by using antibiotic resistance as selection 
marker. This enables the production of attenuated mutant virus, because the wild type 
virus will not outgrow the mutant virus. Nowadays, various CMVs are available as 
BACs, e.g. HCMV and MCMV [25, 26]. 
 
1.3 Clinical Relevance 
HCMV is ubiquitous in the human world population. The seroprevalence ranges from 
20% up to nearly 100%. The prevalence depends on age and socio-economic factors, 
e.g. in adults in less developed countries the seroprevalence is higher in comparison to 
developed countries (reviewed in [27]). Other factors that influence the probability of 
HCMV infection are the availability of healthcare services and the hygiene status [28, 
29]. Most people undergo primary infection as infants and the risk of infection is 
increased if the care of children takes place in groups. HCMV can be shed, among 
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others, via the urine and saliva, which is particularly frequent during the primary 
infection and a reason for the high contagion risk, particularly between small children 
[30, 31]. 
In most cases, the primary infection remains undetected because it is asymptomatic or 
manifests only mild and nonspecific symptoms, e.g. low-grade fever, fatigue or mild 
hepatitis. The course of the disease is mild in immunocompetent people, probably 
because the virus is controlled by the immune system. During pregnancy, primary 
infection can have serious consequences for the foetus. A congenital infection is 
caused by the placental transmission of the virus from the mother to the unborn child. 
For approximately 10% of these children, this can have devastating consequences, 
ranging from hearing impairment to brain damage, causing mental retardation 
(reviewed in [32] and [33]). 
All groups that have undergone a primary infection, including the immunocompetent 
individuals, carry the virus for life. As already described in chapter 1.1, herpesviruses 
establish a life-long persisting infection. During the latent phase of infection, viral 
particles cannot be detected in the host, but the silenced viral genome is episomally 
maintained in the nucleus of latently infected cells [34]. Reactivation events occur from 
time to time, induced for example by stress-induced activation of viral promoters 
(reviewed in [16]). In immunocompetent hosts these small reactivation centers are 
controlled by the immune system and prevent the virus from spreading. People who 
have a compromised immune system, whether by disease or as a result of medication, 
have significantly more severe symptoms, for example hepatitis, retinitis or enteritis 
(reviewed in [32]). This affects allograft recipients, patients with the acquired immune 
deficiency syndrome (AIDS), but also cancer patients receiving chemotherapy. The 
HCMV-related complications in immunodeficient patients, caused by primary infection 
or reactivation of latent virus, require the development of efficient treatment options. 
Nowadays, common therapies against HCMV include the administration of anti-viral 
drugs, such as ganciclovir, cidofovir, fomivirsen or acyclovir, although all of these 
compounds have limitations. The HCMV genome is prone to mutations, which leads to 
the selection of mutants that are resistant to the anti-viral compounds. Moreover, some 
medications have serious side effects. For instance, cidofovir cannot be used in 
patients with renal transplants, because of its nephrotoxicity. (reviewed in [35]) 
Passive immunization was shown to reduce the risk of congenital CMV disease [36], 
but a vaccine against HCMV could not be developed until today, probably due to its 
immune-evasive properties. 
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1.4 Murine CMV as a Model for Human CMV 
The most common and well-established animal model to study CMV infection is the 
mouse model. MCMV and HCMV coevolved with their respective host species and are 
uniquely adapted to it. Therefore, the CMVs infecting mice or humans are not identical, 
but nevertheless evolved genes with related functions. 
MCMV and HCMV share similarities in the sequence for several essential ORFs. For 
example, the proteins M80 and M54 of MCMV, an assembly protein and a DNA 
polymerase, have sequence and functional homologs in HCMV [37, 38], arguing for a 
common ancestry of these genes and of the CMVs in general. Other genes have 
distinct sequences, but similar functions, arguing for converging evolution due to similar 
selection pressures. Therefore, the overall interaction of MCMV and HCMV with their 
respective hosts and their strategies to escape the immune system are conserved. 
Depending on the infectious dose and on the susceptibility of the mouse strain, MCMV 
causes similar clinical manifestations as HCMV in humans. In immunocompetent mice 
the primary infection is almost asymptomatic, but the suppression of the immune 
system of latently infected mice leads to severe organ disease, e.g. pneumonia or 
retinitis [39, 40]. In contrast to HCMV, MCMV is not placentary transmitted, but 
newborn mice infected with MCMV develop diseases similar to the infected human 
newborns, including the infection of the central nervous system [41, 42]. 
In studies with AIDS patients or organ recipients it could be determined that the CD4+ 
and CD8+ T cell responses play a critical role in primary HCMV infection or recurrence 
[43, 44]. The same phenomena were observed in the mouse model [45, 46]. Moreover, 
the cellular and molecular mechanism of the interaction between virus and the immune 
system could be studied in minute detail by experiments with knock-out mice, adoptive 
transfers or monoclonal antibody-mediated depletions of individual components of the 
immune system. 
In conclusion, while the mouse model has limitations to investigate the interaction of 
HCMV and its host, it has significantly contributed to the understanding of the biology 
of CMV infections. Therefore, the findings from the mouse model may help to develop 
new drugs and therapies against HCMV. 
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1.5 MCMV Latency and Reactivation 
MCMV and all members of the Herpesviridae family are able to establish a life-long 
infection in the host. Characteristics of such an infection are an acute phase of viral 
replication and spread in the host, followed by a latent phase in which the silenced viral 
genome is detectable in host cells, but only sporadic replication occurs (reviewed in 
[47]). 
Whether CMVs establish a true latency or if infectious virus persistently replicates 
below the detection threshold is still unclear. Latency is defined as the long-term 
maintenance of viral genomes in the absence of infectious viral particles and the ability 
of the virus to reactivate from the latent state. In contrast, a persistent infection is 
characterized by the permanent presence of replicating viral particles on a low-level. At 
the organism level, it is difficult to exclude if CMV is persistently replicating in some 
parts of the body. For example, infectious viral particles are frequently absent from the 
lungs of an MCMV-infected mouse despite the presence of replicating virus in the 
salivary glands of the same animal [48]. 
It is unlikely that CMV establishes latency in one single cell type, because MCMV 
genomes could be identified in various organs in latently infected mice, for example in 
the bone marrow, spleen, lungs, liver, kidney and in the heart [49-52]. Seckert et al. 
have shown that the liver sinusoidal endothelial cells (LSECs) are a site of MCMV 
latency in the liver [53]. Others have shown that latent viral genomes may be found in 
peritoneal Macrophages [54, 55]. However, it remains unclear, whether macrophages 
are really a site of latency, since viral genomes have been detected in bone marrow 
resident precursor cells of the myeloid lineage [55], and hence of monocytes and 
eventually macrophages. Bone marrow cells and their derivates, the Monocytes, have 
been also detected as a site of HCMV latency [56-59], and their differentiation into 
macrophages was shown to result in virus reactivation [60]. The HCMV latency in 
endothelial cells remains controversial, since viral genomes were detected in 
endothelial cells of the human aorta [61], although it could not be identified in the 
saphenous vein [62]. 
 
The molecular mechanisms allowing that latency is established and maintained remain 
unclear. There are two competing models of latency establishment. Both models 
assume that an infected cell which has once begun to produce viruses cannot become 
a latently infected cell, because it inevitably dies by apoptosis or lysis. However, one 
model is based on the idea that viral proteins promote latency together with cellular 
repressors, which prevent promoter activity [63]. The alternative model assumes that 
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the genomes are silenced immediately upon infection (reviewed in [64]). Therefore, 
according to this model, the decision of a lytic or latent infection might already be made 
after the release of the viral DNA into the cell nucleus. 
The infected cells recognise viral proteins or viral DNA by receptors sensing pathogen 
associated molecular patterns and reacts to viral infection by expressing anti-viral 
compounds [65]. 
 
The initial viral gene expression occurs from the major immediate-early enhancer 
promoter (MIEP) [66] (reviewed in [3]). The MIEP is bidirectional in the MCMV genome, 
and drives the expression of the immediate-early genes ie1/ie3 and ie2 [67]. The genes 
ie1 and ie3 are expressed from the same promoter and share the first three exons, 
while alternative splicing of exon 4 or 5 results in transcription of ie1 or ie3 messenger 
RNA (mRNA), respectively [17]. The protein IE1 was shown to be dispensable for viral 
growth in vitro and for the establishment of latency, as well as for reactivation. 
However, the viral growth of an MCMV lacking ie1 is somewhat attenuated in vivo    
[68, 69]. This may be caused by the fact that IE1 promotes viral gene transcription by 
dispersing Nuclear Domain 10 (ND10) bodies, which are intranuclear defence 
mechanisms to inhibit viral transcription [20]. In contrast, the protein IE3 is essential for 
viral growth in vitro and in vivo [18]. It is critically important for the expression of 
essential early genes, because it counteracts cellular defence mechanism and recruits 
viral and cellular proteins to viral DNA replication domains [19]. The protein IE2 is 
expressed in the opposite orientation relative to IE1 and IE3 and is completely 
dispensable for viral growth in vitro and in vivo and its function is still unknown [70]. 
During the lytic infection, expression from the MIEP occurs in both directions, resulting 
in the transcripts of ie1, ie3 and ie2 mRNAs [71, 72]. New data from my research group 
indicate that the direction of the expression from the MIEP might depend on the cell 
type [73]. 
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Figure 2 Structure and organisation of the MIE region of MCMV. 
The entire major immediate-early enhancer (MIE) region including the exons and introns of the 
genes ie1/3 and ie2 and their related proteins is shown. TF: Transcription factor, 
TFBS: Transcription factor binding site, P: Promoter. (from Simon et al., 2006, [47]) 
 
After the viral genome has entered the cell nucleus, cellular repressors and histones 
are recruited to the incoming, foreign DNA [74]. Histones can be associated with the 
repression of promoter activity, by being deacetylated or methylated. It has been 
shown in vivo that in latently infected cells the cellular repressors YY1, CBF1/RBP-Jk, 
CIR and Daxx are bound to the MIEP [74]. YY1 is a transcription factor, which can act 
as an activator or repressor. In HCMV infection, YY1 was shown to repress the ie1 
gene expression [75]. CBF1/RBP-Jk is a protein which recruits histone deacetylases 
(HDACs) and other corepressors to its binding site (reviewed in [76]). CIR is a 
corepressor, which is recruited to the MIEP to inhibit viral gene expression [74] and 
Daxx is a compound of the anti-viral ND10 complex (reviewed in [77]). The histones 
associated with the MIEP during latency are hypoacetylated and hypermethylated, 
whereby the MIEP is mostly transcriptionally inactive [78]. 
Since CMV lytically replicates in various cell types, the virus needs to overcome anti-
viral responses by different host cells. The viral proteins IE1 and IE3 are not only 
transactivators of early and late viral gene expression, but are also counteracting the 
intrinsic cellular anti-viral response [18-20]. Abundant expression of these proteins 
disperses, the cellular repressors, allowing the RNA polymerase II to bind to the viral 
promoters and initiate transcription of viral genes (reviewed in [64]), [74]. 
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Figure 3 Repression and activation of viral gene transcription. 
Upon entering the cell nucleus, the viral genome is packed with histones, and cellular 
repressors bind to viral promoters. The overexpression of viral proteins can reverse the 
transcriptional repression, which leads to transcriptionally active viral promoters. HDAC: Histone 
deacetylase, CR: cellular repressors, H: Histone, VP: viral proteins, Ac: acetylated histone. 
 
These data have led to the hypothesis that the virus can establish latency if the cellular 
repressors silence the MIEP successfully before the immediate-early genes ie1 and ie3 
are overexpressed (reviewed in [64]). If this does not occur, the expression of viral 
IE proteins counteracts the cellular repressors, allowing the virus to enter the lytic 
cycle. Both scenarios have advantages and disadvantages for the virus. The lytic 
infection of cells allows the virus to spread in the body, but the latent infection is 
required for viral long-term maintenance in the host. 
 
The adaptive immune system also contributes to the repression of viral replication. 
Although MCMV has developed strategies to escape recognition by immune cells 
(reviewed in [79]), it cannot completely prevent that the infected cell presents viral 
antigen on its surface and thus can be recognised by cells of the immune system, 
especially if the virus tries to reactivate from latency [80]. 
 
However, the transcription of viral genes during latency is not completely suppressed, 
since the transcription from the MIEP occurs sporadically. mRNA of the genes ie1 and 
ie2 could be detected in the lungs of latently infected mice while transcripts of the 
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genes ie1 and ie3 were identified in latently infected LSECs [53, 71]. This occurred in 
the absence of early and late genes transcription, which argues against a reactivation 
of the virus [81]. 
Continuous modification of histones takes place in metabolically active cells, which 
might lead to a temporary opening of the MIEP, allowing the binding of RNA 
polymerases. Hence it is assumed that the virus reactivates after a change of the cell 
metabolism or of the cell environment. This notion is supported by MCMV reactivation 
from latently infected macrophages upon stimulation with thioglycollate [54]. 
Furthermore, the MIEP has binding sites for inflammation or stress induced 
transcription factors, like NFκB and AP-1 (reviewed in [16]). Therefore a pro-
inflammatory environment may promote viral reactivation [82]. Virus reactivation may 
also be induced by the elimination of the adaptive immune system, such as CD4+ T 
cells, CD8+ T cells, B cells and natural killer cells (NK cells) [83]. It remains unclear 
whether the reactivation is due to the lack of the interaction of immune cells with the 
latently infected cell or whether this may occur due to a change of the cytokine profile 
associated with the depletion. Nevertheless, both the increased production of cytokines 
and the absence of the immune system may be triggers for viral reactivation after 
organ transplantation. Interestingly, experimental allogeneic kidney transplants induced 
an increase of inflammatory cytokines in the transplanted tissue and MCMV 
reactivation of latency [84]. 
 
In summary, the reactivation of latent CMV can be triggered by several factors. These 
factors include cellular differentiation and enhanced cellular activity accompanied with 
the remodelling of the chromatin structure, the down-regulation of repressive 
transcription factors and up-regulation of activating transcription factors. In addition, the 
production of inflammatory cytokines upon tissue damage can induce CMV reactivation 
[84]. One might argue that the capacity of CMV to reactivate from latency is a survival 
strategy, developed over millennia, to escape from injured or moribund hosts. 
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1.6 The Role of the Innate Immune System in MCMV Infection 
The innate immune system is the first line of defence against an infection. Components 
of the innate immune system include the complement system, cytokines, NK cells and 
professional antigen-presenting cells (APCs) like macrophages and dendritic cells 
(DCs). 
The complement system consists of different proteins, which bind to opsonised 
pathogens or to the pathogen’s cell surface and induce its lysis. Thus, it is involved in 
the clearance of infections. 
The activation of the immune system is mediated by cytokines and phagocytic cells. 
Professional APCs internalise pathogens and apoptotic bodies from infected cells, 
processing the degraded proteins and presenting them to cells of the adaptive immune 
system. Moreover they recruit other immune cells to the site of infection by secreting 
cytokines. 
Interferons (IFNs) are cytokines which play an important role in the control of viral 
infection. Relative to the receptor they bind to, there are two main classes of IFNs: type 
I IFNs (IFN-I) and type II IFNs (IFN-II). The IFN-I binds to IFN-I receptors and consists 
of IFNβ and IFNα variants, whereas there is only one IFN binding to IFN-II receptor: 
IFNγ. IFN signalling leads to the nuclear translocation of STAT molecules and 
expression of multiple anti-viral genes. IFNγ signalling is dependent on the 
phosphorylation of STAT1 homodimers, whereas IFN-I signalling needs STAT1 and 
STAT2 heterodimers. Due to the different STAT molecules involved in downstream 
signalling, the activation of IFN-I or II receptors results in the expression of different 
genes. (reviewed in [85] and [86]) 
The expression of IFNγ and its signalling via the IFN-II receptor decreases viral growth 
(reviewed in [85]) [87] and promotes the expression of major histocompatibility complex 
(MHC) class II (MHC-II) in macrophages [88] and MHC class I (MHC-I) in all cells 
(reviewed in [89]). Splenic stromal cells in the marginal zone produce high amounts of 
IFN-I in response to MCMV infection, which activates immune cells like NK cells and 
recruits them to the site of infection [90]. DCs are responsible for the second wave of 
IFN secretion in MCMV infection [87]. They are classified into two groups, based on 
their surface markers and function: plasmacytoid DCs (pDCs) and conventional DCs 
(cDCs). The pDCs localise mainly to the blood and the lymphoid tissues. Upon 
detection of an infection, they release large amounts of IFNα and present antigens on 
their cell surface to activate other immune cells, e.g. NK cells [91]. The cDCs are found 
in lymphoid and non-lymphoid tissues and are divided in many different subsets. 
(reviewed in [92]). cDCs which express the co-receptor CD8 have an important role in 
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priming CD8+ T cells via cross-presentation during acute MCMV infection [93] 
(reviewed in [94]). DCs are also important early upon MCMV infection because they 
activate NK cells and promote the expansion of Ly49H+ NK cells [95]. 
NK cells are involved in the controlling of tumour cells and viral infections, by the 
production of cytokines and cytotoxic activity. They express activating and inhibitory 
receptors simultaneously to distinguish between healthy and degenerated or virus-
infected cells (reviewed in [96]). The inhibitory receptors recognise MHC-I molecules 
and prevent the cytotoxic activity of the NK cell. Virus-infected cells often down-
regulate the presentation of MHC-I molecules to evade the cytotoxic T lymphocyte 
(CTL)-mediated killing (reviewed in [96]). In the absence of MHC-I the binding of 
activating receptors of NK cells to their ligands prevails (e.g. NKG2D binding to Rae-I 
[97], Mult-1 [98, 99] or H60 [100, 101]) which initiates the killing of the infected cell 
(reviewed in [102]). 
NK cells may also become highly activated through the binding of the Ly49H receptor 
to its ligand, the MCMV protein m157 [103, 104]. The expression of the Ly49H receptor 
is strain dependent; C57BL/6 mice express it, and hence their NK cells provide strong 
immune protection against MCMV infection. In contrast, Balb/c mice and other Ly49H-
deficient strains, are susceptible to MCMV infection [105]. NK cells act against the 
virus-infected cells by secreting cytotoxic granules, IFNγ and by helping in activating 
the T cells [106, 107]. The NK cell role in the control of CMV is evolutionarily conserved 
and they are not only important to combat MCMV [108-110], but also HCMV [111]. 
 
1.7 The Role of the Adaptive Immune System in MCMV Infection 
The cells of the adaptive immune system are divided into B and T lymphocytes. The B 
cells mediate the humoral response to infections, while the T cells are responsible for 
the cellular response. The humoral response is also called the antibody-mediated 
response, where antibodies target the pathogens in the extracellular body fluids. In the 
cellular response, the T cells target the infected cells and thus the intracellular 
pathogens. Both subsets play an important role during the acute infection with MCMV, 
but also during its reactivation. While the T cells are able to control a CMV infection 
without B cells [83], the B cells alone are not able to combat CMV [112]. 
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1.7.1 The Humoral Response to Infections 
B cells are activated by recognising viral antigens with their immunoglobulin (Ig) 
receptors on the cell surface. In the case of protein antigens a signal cascade leads to 
the internalisation of the antigenic protein bound to the B cell receptor (BCR), followed 
by processing and presentation of protein-derived peptides on MHC-II. B cells require 
the help of the peptide-specific CD4+ T-helper cells to become fully activated. Upon 
CD4+ T cells stimulation, the B cells proliferate and form germinal centres in secondary 
lymphoid organs, which leads to B cell differentiation into plasma cells and 
establishment of B cell memory (reviewed in [113, 114]). Interaction between the 
follicular CD4+ T-helper cells and B cells initiates the Ig class-switch of B cells, resulting 
in the secretion of antigen-specific IgG antibodies. The binding of antibodies to viral 
antigens can neutralise the viruses and thus inhibit the viral in vivo dissemination. 
Furthermore, opsonisation of viruses by antibodies labels them for detection of 
components of the innate immune system e.g. the complement system or the 
phagocytic cells. MCMV and HCMV may be neutralised by antibodies against the viral 
surface glycoprotein B (gB) [115, 116]. 
The role of antibody-secreting B cells in MCMV infection was defined in experiments 
with B cell-deficient mice. The presence of MCMV-specific antibodies does not 
significantly decrease viral titres in organs during acute infection, but limits the spread 
of the virus upon reactivation caused by immune suppression of latently infected mice 
[83]. The establishment of latency, however, is not prevented [117, 118]. In clinical 
tries, the passive immunisation is experimentally used as therapy, to suppress the 
symptoms of HCMV infection in immunocompromised patients or foetuses [36]. 
 
1.7.2 The Cellular Response to Infections 
The cellular response to infections is mediated by T cells. They can either directly act 
on infected cells inducing their apoptosis, or facilitate the activation of phagocytic cells 
which subsequently engulf apoptotic bodies or pathogens. 
Lymphoid cells of the B cell lineage undergo their maturation in the bone marrow, but 
the maturation of T cells occurs in the thymus. The T cell maturation in the thymus is 
divided into several steps, starting with immature T cells expressing neither CD4 nor 
CD8, transitioning through the double-positive (CD4+ CD8+) phase and ending with 
naive T cells which express either the CD4 or the CD8 co-receptor (reviewed in [119]). 
CD4+ T cells are termed T-helper cells, because they activate immune cells and 
promote the survival of other T cells (reviewed in [120]). The co-receptor CD4 binds to 
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the constant part of the MHC-II, which is mainly expressed on APCs. The co-receptor 
CD8, expressed on CTLs, facilitates the binding to the MHC-I (reviewed in [121]). 
The binding to the MHCs is facilitated by the T cell receptors (TCRs), expressed on 
every T cell. Due to a selection process during the T cell maturation, each T cell clone 
expresses a different TCR, which is composed of a constant region and a variable 
region, by which it binds to the MHC. The somatic recombination of the variable (V), 
the diversity (D) and the joining (J) gene segment during the maturation process 
rearrange the VDJ locus into a sequence that differs from each cell (reviewed in [122]). 
The process depends on the recombination-activating genes 1 and 2 (RAG-1 and 
RAG-2) thus ensuring that each T cell gets a unique TCR with different combinations of 
the V, D and J segments, but also of additional codons introduced at random during the 
rearrangement process (reviewed in [123]). 
The MHC-I is expressed on every nucleated cell within the body. MHC-I present 
constantly short peptides on the cell surface, which are derived from the proteins that 
the cell has produced. Old or defective proteins are degraded by the proteasome and 
the resulting peptides are transported via a transporter complex, called transporter 
associated with antigen processing (TAP), into the endoplasmatic reticulum (ER). The 
peptide loading complex, that allows the loading of the peptide on the MHC-I, is directly 
bound to the TAP. Peptides are actively transported via the TAP and loaded onto the 
MHC-I. The peptide loaded MHC-I then may dissociate from the loading complex and 
is transported via the Golgi to the cell surface, where cells of the immune system can 
bind to and initiate cell death once an antigenic peptide (e.g. from a virus) has been 
recognised. (reviewed in [124] and [125]) 
Efficient binding of the TCR to the MHC-I, depends on the peptide presented by the 
MHC and the presence of co-stimulatory molecules on the surface of the target cell. 
The expression of co-stimulatory ligands is stress-induced, for example in an infected 
or degenerated cell. These ligands increase the signal transduction and prolong the 
binding of the T cell to its target, contributing to the activation of T cells. The T cell 
responds with the secretion of molecules resulting in the activation of the apoptotic 
pathway in the target cell, if a strong signal is provided by multiple TCRs bound to their 
ligands. (reviewed in [126] and [127]) 
However, some pathogens have developed strategies to escape this control 
mechanism. MCMV acquired several genes counteracting the peptide presentation on 
MHC-I, termed immunoevasions (Figure 4). For example, m152 encodes for a protein 
which retains the MHC-I in the ER and prevents its transport to the Golgi [128, 129]. 
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Another protein m06 leads to the transport of MHC-I from the ER into a lysosome and 
to its degradation [130]. HCMV acquired proteins with similar functions [131-133]. 
 
 
 
Figure 4 Model for the action of two immunoevasions of MCMV. 
The antigen is degraded by the proteasome and peptides are transported via TAP into the ER, 
where the peptides are loaded onto the MHC-I. The Protein m152 retains the MHC-I in the ER 
and prevents its presentation on the cell surface. The protein m06 leads the MHC-I to be 
transported to the lysosomes and thus, to its degradation. TAP: transporter associated with 
antigen processing, ER: endoplasmatic reticulum, ERGIC: ER-Golgi intermediate compartment. 
(modified from Reddehase, 2002 [134]) 
 
The activation of T cells usually takes place in lymphoid organs. In response to an 
infection, professional APCs, in particular DCs mature and migrate to the lymphoid 
organs, such as spleen and lymph nodes. Here they encounter the resting naive and 
memory T cells, present them the antigenic peptides, resulting in T cell activation 
(reviewed in [135]). APCs engulf and digest dead cells in a site of inflammation and the 
short peptides derived from the degraded proteins are loaded on the MHC-I and MHC-
II and presented to CD8+ and CD4+ T cells, respectively. The activation of CD8+ T cells 
may also occur if the APC is infected with intracellular pathogens such as viruses and 
the antigenic peptides are presented directly on the MHC-I of the infected cell. 
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Moreover, naive CD8+ T cells need additional cytokine signals for activation. The 
proliferation of a T cell specific for the peptide presented on the MHC results in a 
population of T cell clones with the same TCR capable of targeting and neutralising 
antigens. (reviewed in [136]) 
Most of the expanding T cells are specific for only a few antigenic peptides, termed 
immunodominant peptides. Besides other characteristics, these peptides are 
preferentially generated and loaded on the MHC and able to trigger the most intense 
immune response, (reviewed in [137]). Upon antigen encounter, T cells expand and 
differentiate into effector or memory cells, depending on the presence of the 
corresponding inflammatory cytokines. The activated effector T cells down-regulate 
receptors responsible for their residence in the lymphoid organ and up-regulate 
receptors specific for binding to endothelial cells in blood vessels. Thus, they leave the 
central lymphoid organ, enter the peripheral circulation and migrate to the site of 
infection, where they are able to leave the blood vessels by active extravasation 
(reviewed in [138]). Some T cells differentiate into memory T cells upon antigen 
encounter and reside in organs and lymphoid organs for the rest of their life (reviewed 
in [139]). The clonal expansion and maturation of effector T cells requires time to 
provide sufficient amounts of fully activated cells. Therefore, the innate immune system 
keeps the pathogens in check immediately upon infection, until more adaptive immune 
cells are recruited and expanded. If the infection is successfully controlled, the 
cytokines that promote T cell proliferation are down-regulated and thus the T cells lack 
the signals that they need for survival. As a result, they undergo apoptosis [140]. 
However, the memory T cells may survive for a long time in the lymphoid organs, 
because here they are exposed to additional survival stimuli, for instance 
interleukin(IL)-15 (reviewed in [141]). 
 
In an ongoing infection, three subsets of CD8+ T cells emerge: naive T cells, central 
memory T cells (TCM) and effector memory T cells (TEM) (reviewed in [142]). These 
subsets can be distinguished by the expression of the receptors CD44, CD62L or 
CD127 [143]. Naive T cells have low expression of CD44, but high expression of 
CD62L and CD127. CD62L, known as L-Selectin, is an adhesion molecule which binds 
to a ligand mainly expressed on cells of the secondary lymphoid organs [144]. CD127 
is the alpha chain of the receptor for IL-7, a cytokine which is important for the survival 
of naive and memory T cells (reviewed in [145]). TCM cells are characterised by the high 
expression of CD62L, CD127 and CD44. CD44 is an adhesion molecule which is 
expressed on activated T cells and promotes the extravasation of T cells to sites of 
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inflammation [146]. Effector and effector memory T cells express low amounts of 
CD62L, show low or intermediate expression of CD127 and high expression of CD44 
[143]. 
During an infection, primed naive T cells undergo the expansion and the differentiation 
phase, resulting in large amounts of fully functional effector T cells. When the acute 
infection is cleared, up to 95% of the pathogen-specific effector T cells die, while the 
remaining cells from the memory T cell pool persist in the long-term, even in the 
absence of antigen (Figure 5). This pool of memory cells is mainly composed of T cells 
with a TCM phenotype (reviewed in [142]). 
 
 
 
Figure 5 Dynamic of CD8+ T cells during and after an infection. 
Naive T cells are stimulated by an antigen and proliferate and differentiate into effector T cells 
and memory T cells. Without the stimulating antigen, e.g. after the infection is cleared, effector 
T cells undergo cell-death, while the memory T cells remain in the long term. N: Naive T cell; 
E: Effector T cell. (from Wherry, E.J. and Ahmed, R., 2004 [143]) 
 
1.7.3 Modulation of the Cellular Immune System by CMV 
During CMV infection, some of the virus-specific T cells undergo the typical fast 
expansion in the acute phase, followed by a contraction after the infection is cleared 
and are marked by TCM phenotype [147] (Figure 6). On the other hand, several CMV-
specific T cells accumulate (or inflate) over time and do not contract, a phenomenon 
termed memory inflation (MI) [148]. These T cells are specific for the certain peptides 
and have a TEM phenotype, characterised by low expression of CD62L and CD127 
receptors on the cell surface [147, 149, 150]. 
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Figure 6 Development of CMV-specific memory CD8+ T cells. 
Non-inflationary T cells expand in the acute phase of infection, contract after the virus infection 
is cleared and the memory T cells remain on a low level. These cells develop a TCM phenotype. 
Inflationary T cells expand slowly in the acute phase of infection but continue to accumulate 
during latency. These cells develop a TEM phenotype. (modified from O’Hara et al., 2011 [151]) 
 
In latently infected people, ~10% of the CD4+ and CD8+ T cells are HCMV-specific, with 
the consequence that these T cells dominate the T cell pool [152]. Similar results were 
observed in mice, where one year after the infection already 20% of the CD8+ T cells 
were found to be specific for one single MCMV-epitope [148]. During the acute phase 
of infection, a broad T cell response is observed against different MCMV epitopes. In 
the latent phase, however, five inflationary viral epitopes dominate the pool of MCMV-
specific T cells in C57BL/6 mice [147]. This strong response affects the T cell pool in 
general, because the absolute count of CD8+ T cells is significantly higher in MCMV-
infected mice than in uninfected ones [153]. 
Why only some CMV-specific T cells show this accumulation is not fully understood, 
but several contributing factors have already been identified. It has been shown that 
the accumulation of inflationary T cells is not impaired in mice which are unable to 
perform cross-presentation [93]. However, the presence of CD4+ T cells promotes MI 
[46, 154]. Furthermore, it was recently shown that the context of gene expression and 
competition for antigen presentation plays a role in the dominance of individual 
peptides during latency [155, 156]. The expression pattern of the gene which encodes 
the peptide influences the kinetic of the peptide-specific T cells. A foreign peptide 
inserted in an immediate-early gene results in inflationary T cells, whereas the same 
peptide inserted in an early gene results in non-inflationary T cells. Others have shown 
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that the initial viral replication, or continuous replication events during MCMV latency is 
not necessary to drive MI. Systemic infection with a spread-deficient MCMV, which 
lacks the essential glycoprotein gL and is therefore unable to replicate, drove the 
accumulation and maintenance of MCMV-specific CD8+ T cells with a TEM phenotype 
[157]. It is therefore assumed that persistent viral gene expression triggers MI. 
It remains unclear, how the pool of virus-specific T cells sustains its number over time. 
While the recruitment of novel naive T cells into the pool of inflated cells is in theory 
possible, MI occurred to the same extent in thymectomised mice [158]. It was shown 
that CMV-specific TEM cells are short-lived, because their numbers decrease after 
being adoptively transferred into a recipient mouse, infected with MCMV, and it is 
therefore unlikely that they have proliferative potential [150]. Hence, it is assumed that 
the size of the TEM cell pool is maintained by the recruitment of other T cells. On the 
other hand direct antigen presentation by non-hematopoietic cells was shown to drive 
the proliferation of MCMV-specific T cells in the lymph nodes during latency [159]. 
There, it was shown that adoptively transferred TCM cells from latently infected 
secondary lymphoid organs can proliferate in recipient mice that are also MCMV-
infected, in contrast to TEM cells from latently infected lungs, which failed to expand 
upon adoptive transfer. 
 
Since TCM cells are more abundant than TEM in the lymph nodes, it is considered that 
local persistent viral gene expression stimulates the TCM cells to proliferate, differentiate 
into TEM cells and to migrate out of the central lymphoid organs into the periphery and 
the organs. On the other hand, a proof for the continuous proliferation and 
replenishment of the TEM cell pool by TCM progenitors rests on experiments with 
adoptively transferred cells, but a direct proof in absence of adoptive transfer has 
remained elusive. 
 
1.8 Conditional Gene Expression System (Cre/loxP) 
One method to investigate the function of a protein in an organism or a pathogen is to 
silence its gene, e.g. by the removal of the coding gene sequence from the genome, or 
by the introduction of a nonsense mutation. The function of the missing protein may be 
thus identified by the change in phenotype. However, if the silenced gene is essential, 
it will inevitably lead to the death of the organism and therefore the study of the exact 
function of this protein will be severely limited. In such cases it is beneficial if the 
expression or the function of the protein can be controlled in an inducible manner. This 
can be achieved, for example, with temperature-sensitive mutations, in which an 
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increase or decrease of the temperature results in a non-functional protein, although 
this exact method cannot be used for organisms which have to keep a constant body 
temperature (e.g. mammals or birds). 
The Cre/loxP system is a genetic system that offers an opportunity to conditionally 
control the gene expression. The enzyme Cre and its target, the loxP sequence, are 
derived from the bacteriophage P1 [160]. Cre means literally “causes recombination” 
and is a 38 kDa enzyme which acts in trans to promote recombination. The sequence 
on which the enzyme acts on is called loxP site: locus of crossing over (x), P1. If two 
loxP sites, 34 base pairs (bp) in length, flank a gene locus, Cre recombinase may 
recombine the intervening sequence. If two directly repeated loxP sites flank the gene, 
the sequence between them is excised, whereas DNA segment flanked by inverted 
loxP sites are inverted in the presence of Cre recombinase [161, 162]. The Cre-
mediated site-specific recombination at loxP sites works in mammalian cell lines, as 
well as in vivo [163]. Mating mice which express the Cre enzyme with a mouse line 
which has a DNA segment flanked with loxP sites leads to the excision of the 
intervening segment in the murine progeny [164]. 
Various mouse strains expressing the Cre enzyme under the control of different 
promoters are readily available, allowing ubiquitous as well as tissue-restricted 
expression of Cre (reviewed in [165]). It has been shown in several studies that the 
Cre/loxP system also works when their components were integrated into viral genomes 
including herpesviruses like MCMV [166-169]. However, even if the use of the Cre/loxP 
system has great advantages in the investigation of tissue-specific activity of proteins, 
the function of genes whose expression is essential for the survival of the organism 
cannot be studied. This limitation has been mitigated by the development of a system 
in which the activity of the Cre enzyme can be temporarily controlled.  
To produce an inducible Cre enzyme, the ligand-binding domain of the oestrogen-
receptor (ER) was fused to the Cre [170]. Upon activation by oestrogen binding, the 
oestrogen receptor translocates into the nucleus and activates the transcription of 
oestrogen inducible genes [171]. The activity of Cre was controlled by the addition of 
an oestrogen, estradiol or its antagonist 4-hydroxytamoxifen. Both bind to the 
oestrogen-receptor and lead to the translocation of Cre into the cell nucleus. Without 
estradiol or Tamoxifen (Tam), the Cre-ER remains in the cytoplasm due to the 
interaction of the oestrogen receptor with the heat-shock protein 90 (Hsp90) [172, 173]. 
Due to uncontrolled nuclear translocation caused by naturally circulating oestrogen, the 
ER receptor cannot be used for targeted induction of Cre activity in vivo. To circumvent 
this problem, a mutated murine oestrogen receptor (ERT) was developed, which cannot 
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bind oestrogen, but remains sensitive to 4-hydroxytamoxifen [174, 175], with no or only 
minor background recombination in the absence of Tam [176-178]. A mouse line 
expressing this fusion-protein Cre-ERT was created, in which the enzyme is expressed 
under the control of the Rosa26 (R26) promoter [179]. The R26 locus is expressed 
ubiquitously in embryonic and adult tissues and thus is highly suitable for ubiquitous 
Cre expression [179, 180]. This system allows the temporal control of Cre activity by 
the administration of Tam and thus the excision of DNA segments, flanked with loxP 
sites (Figure 7). 
 
GOI
loxP loxP
Cre-
recombinase
GOI
loxP
loxP
 
 
Figure 7 Overview about an induced knock-out by the Cre/loxP system. 
The ORF of the gene of interest (GOI) is flanked by loxP sites. The enzyme Cre recombinase 
binds to the loxP sites and recombines the GOI. What remains is the genome without the GOI 
and a plasmid-like structure.  
 
The most common routes of Tam administration are the administration into the 
stomach with a feeding needle and the injection into the abdominal cavity [181-183]. 
However, both methods are applied for a period of 5 days only, because they are 
associated with high levels of stress for the animals. Alternatively, the administration 
can be done via food pellets, enriched with a certain concentration of Tam [184] and 
the concentration of 360 mg/kg is described as sufficient to achieve recombination by 
Cre, fused to the mutated murine oestrogen receptor ERT2 (Cre.ERT2) [184]. The 
efficiency of recombination of Cre.ERT2 is not described yet, when induced by Tam 
administration via chow and expressed from the Rosa26 promoter. With oral 
administration or intraperitoneally (i.p.) injection of Tam for 5 days, recombination could 
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be achieved in all tissues of the adult animal [176], with the exception of the brain, 
where no Cre.ERT2 expression was observed. This circumstance is of minor 
importance for studying MCMV T cell responses in the blood or secondary lymphoid 
organs, because MCMV infection of the brain has not been described until now, if the 
infection was performed i.p. Up to date, a Cre.ERT2-mediated recombination, induced 
by the administration of Tam with chow, is described only in systems in which the Cre 
recombinase is expressed under cell type-specific promoters [184-186]. 
 
1.9 Objectives of the Work 
It is generally accepted that persistent viral gene expression stimulates CMV-specific 
CD8+ T cells to proliferate. During CMV infection, some virus-specific inflationary CD8+ 
T cells with a TEM phenotype progressively accumulate through the lifetime of the 
latently infected host [147, 149, 150]. It is assumed that the large population of MCMV-
specific TEM cells is highly dynamic and composed of newly recruited cells, because the 
short-lived TEM cells are believed to proliferate only partially and therefore contribute 
only limited to the maintenance of MI [150]. TCM cells, isolated from latently infected 
secondary lymphoid organs were able to proliferate upon transfer in infected mice, 
whereas TEM cells isolated from the latently infected lungs did not [159]. However, 
these results were obtained by adoptive transfers of T cells, thus in an artificial system. 
 
In this study the effect of persistent viral gene expression on the maintenance of MI 
was to be analysed. For this purpose, the immediate-early genes ie1 and ie3 of MCMV 
were chosen, because their transcription is detectable in latently infected organs 
months after infection, hence in the absence of viral particles [72]. The ie1/3 gene locus 
was to be flanked with loxP sequences to generate the recombinant virus MCMV 
IE1/3flox. The loxP sites are targets for the Cre recombinase and leads to the enzymatic 
excision of the framed DNA fragment. C57BL/6 mice expressing the inducible Cre 
recombinase Cre.ERT2 ubiquitously under the control of the Rosa26 promoter were to 
be infected with either MCMV IE1/3flox or MCMV wild type (WT). Cre.ERT2 is inactive 
unless it is activated by Tam. The activity of the Cre recombinase could be controlled 
by administer Tam containing chow to the mice, and switched on once the MCMV 
infection had reached the latent state. In this phase of infection MI is established and 
the effect of the ie1/3 knock-out can be monitored for the further course of CD8+ T cell 
accumulation. 
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In the first part of the study, it was found that Tam induced Cre.ERT2 had an 
unexpected direct influence on the composition of the CD8+ T cell pool, mainly by 
killing the proliferating cells. Due to these results, it was decided to examine the 
different CD8+ T cell populations in latently infected spleens for their susceptibility to 
Cre-mediated toxicity. The spleen is a secondary lymphoid organ, in which TCM and 
naive T cells, as well as TEM cells are located [187, 188], and hence allowed the 
identification of the T cell subset which underwent apoptosis due to Cre-mediated 
toxicity. Results might give an indication of the cell type that contributes to the 
accumulation of inflationary CD8+ T cells. 
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2 Material and Methods 
 
2.1 Working Concentrations of Antibiotics 
Antibiotic final concentration 
Ampicillin (Amp) 50 µg/ml 
Chloramphenicol (CAM) 25 µg/ml 
Kanamycin (Kn) 20 µg/ml 
 
2.2 Chemicals and Reagents 
The chemicals required for the solutions, buffers and media were obtained from the 
companies ROTH (Karlsruhe, DE), Merck (Darmstadt, DE), Avantor (Center Valley, 
PA, USA) and Sigma-Aldrich (St. Louis, MO, USA). The antibiotics used were supplied 
by ROTH (Karlsruhe, DE) and Serva (Heidelberg, DE). 
 
Brefeldin A cell signalling technology (Danvers, MA, USA) 
CompBeads BD (Franklin Lakes, NJ USA) 
Dimethyl sulfoxide (DMSO) euroclone (Pero, IT) 
GelRed Biotium (San Francisco, CA, USA) 
Heparin Ratiopharm (Ulm, DE) 
Isofluran Abbott (Wiesbaden, DE) 
Kanamycin Sigma-Aldrich (St. Louis, MO, USA) 
Millipore water Merck Millipore (Billerica, MA, USA) 
NaPyr (N-nitroso-alpha- 
acetoxy-pyrrolidine) 
life technologies (Carlsbad, CA,USA) 
Teklad CRD Tam400/CreER Harlan Teklad (Indianapolis, IN, USA) 
Trypan Blue Fluka analytic (Sigma-Aldrich) 
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2.3 Tissue Culture Media and Reagents 
 
Dulbecco's modified Eagle's 
medium (DMEM) 
Sigma-Aldrich (St. Louis, MO, USA) 
Fetal Calf Serum (FCS) biochrom (Berlin, DE) 
Glutamine life technologies (Carlsbad, CA,USA) 
IFNß PBL Interferon Source (Piscataway, NJ, USA) 
Fixation buffer eBioscience (San Diego, CA, USA) 
Fugene HD Transfection Reagent Promega (Madison, WI, USA) 
Liver Digest medium life technologies (Carlsbad, 
CA,USA) 
Liver Digest medium life technologies (Carlsbad, CA,USA) 
Liver perfusion medium life technologies (Carlsbad, CA,USA) 
Opti-MEM I Reduced Serum 
Medium 
life technologies (Carlsbad, CA,USA) 
PBS (phosphate buffered saline) 137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 * 2 H2O 
2 mM KH2PO4 
adjust pH to 7.4 
Penicillin/Streptomycin life technologies (Carlsbad, CA,USA) 
Percoll biochrom (Berlin, DE) 
Permeabilization buffer eBioscience (San Diego, CA, USA) 
Roswell park Memorial Institute 
medium (RPMI) 
Sigma-Aldrich (St. Louis, MO, USA) 
Tam for cell culture Sigma-Aldrich (St. Louis, MO, USA) 
Trypsin life technologies (Carlsbad, CA,USA) 
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2.4 Buffers and Solutions 
 
Ammonium-Chloride-Potassium 
(ACK) lysis buffer 
155 mM NH4CL 
10 mM KHCO3 
1 mM ETDA 
adjust with H2O to 900 ml 
adjust pH to 7.8 with 1 M NaOH 
adjust with H2O to 1000 ml 
sterilising by autoclaving or sterile filtration 
agarose gel Biozym (Hessisch Oldendorf, DE) 
D-biotin 0.2 mg/ml 
sterilising by sterile filtration 
Fluorescence activated cell 
sorting (FACS) buffer 
PBS + 2% FCS 
Gelatine Sigma-Aldrich (St. Louis, MO, USA) 
Hank’s Balanced Salt Solution 
(HBSS) 
AppliChem (Darmstadt, DE) 
L-leucin 10 mg/ml 
sterilising by sterile filtration 
Luria-Bertani (LB)-full medium BD (Franklin Lakes, NJ, USA) 
lysis buffer 1 M Tris (pH 8) 2.5 ml 
10% SDS  2.5 ml 
0,5 M EDTA                         10 ml 
H2O   35 ml 
total volume  50 ml 
sterilising by autoclaving 
1xM9 medium Na2HPO4  6 g 
KH2PO4  3 g 
NH4Cl   1 g 
NaCl   0,5 g 
adjust with H2O to 1000 ml 
sterilising by autoclaving 
5x M63 salts (NH4)2SO4  10 g 
KH2PO4  68 g 
adjust with H2O to 800 ml 
adjust pH to 7.0 
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sterilising by autoclaving 
McConkey agar BD (Franklin Lakes, NJ, USA) 
McConkey plates McConkey agar 10 g 
adjust with H2O to 225 ml 
sterilising by autoclaving 
add 25 Galactose 25 ml 
add appropriate antibiotics 
Methylcellulose Carboxymethylcellulose  3.75 g 
adjust with H2O to  232 ml 
sterilising by autoclaving 
add: 
FCS    25 ml 
2x DMEM   232 ml 
Glutamine   5 ml 
non-essential aminoacids 2.5 ml 
Penicillin/Streptomycin 5 ml 
Minimal plates containing 2-
deoxy-galactose (DOG) 
and CAM 
agar   4 g 
adjust with H2O to 200 ml 
sterilising by autoclaving 
add: 
5x M63 salts  50 ml 
1 M MgSO4  0.5 ml 
D-biotin  1.25 ml 
L-leucin  1.1 ml 
10% glycerol  5 ml 
10% DOG  5 ml 
CAM                           20 µg/ml 
solid medium 1.5% agar BD (Franklin Lakes, NJ, USA) 
15% sucrose-virus standard 
buffer (VSB) 
sucrose  75 g 
adjust with VSB to 500 ml 
sterilising by autoclaving 
10x TRIS-Borate-EDTA (TBE) 
buffer 
TRIS    108 g 
Boride acid   55 g 
adjust with H2O to  900 ml 
0.5 M Na2EDTA (pH 8) 40 ml 
adjust pH to 8.0 
Material and Methods 
28 
 
adjust with H2O to 1000 ml 
sterilising by autoclaving 
TE-buffer 1 M TRIS (pH 8) 10 ml 
Na2EDTA (pH 8) 200 µl 
adjust with H2O to 800 ml 
adjust pH to 8.0 
adjust with H2O to 1000 ml 
sterilising by autoclaving 
VS Buffer TRIS/HCl  6.055 g 
KCl   0.895 g 
EDTA (Na2 salt) 1.86 g 
adjust with H2O to 800 ml 
adjust pH to 7.8 with HCl 
adjust with H2O to 1000 ml 
sterilising by autoclaving 
 
2.5 Kits, Size Standards and Enzymes 
The kits used to isolate Plasmids or BACs from bacteria, and DNA from polymerase 
chain reaction (PCR) samples or agarose gels were obtained from Qiagen (Hilden, 
DE): “QIAGEN Plasmid Mini Kit”, “QIAGEN Plasmid Maxi Kit”, “QIAGEN Large-
Construct Kit”, “QIAquick Gel Extraction Kit” and “QIAquick PCR Purification Kit”. To 
isolate viral DNA the “High Pure Viral Nucleic Acid Kit” from Roche (Mannheim, DE) 
was used. Restriction enzymes were obtained from NEB (Ipswich, MA, USA). 
Proteinase K and size standards “GeneRuler 1 kb DNA Ladder Plus” and “GeneRuler 1 
kb DNA Ladder” were obtained from Fermentas (Thermo Fisher Scientific, Waltham, 
MA, USA).Thermostable polymerases were obtained from NEB (MA, USA) and Bioline 
(Luckenwalde, DE). 
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2.6 Peptides/ Antibodies/ Dextramer 
2.6.1 Peptides 
Peptides were synthesized and HPLC purified (65 – 95% purity) in the research group 
“Peptide Synthesis” of Werner Tegge at the Helmholtz Centre for Infection Research 
(HZI). 
 
ORF Haplotype Sequence 
IE3 (MCMV) Kb 416RALEYKNL423 
M45 (MCMV) Db 985HGIRNASFI993 
M38 (MCMV) Kb 316SSPPMFRV323 
gB (HSV-1) Kb 498SSIEFARL505 
 
2.6.2 Anti-Mouse Antibodies 
 
Antibody Fluorochrom Company 
 
anti-CD3 
 
Allophycocyanin-
eFluor780 
clone 17A2; eBioscience, San Diego, CA 
 
anti-CD4 
 
Pacific Blue 
 
clone GK1.5; Biolegend, San Diego, CA 
 
anti-CD8a 
 
PerCP-Cy5.5 
 
clone 53-6.7; Biolegend 
 
anti-CD44 
 
AlexaFluor700 
 
clone IM7; Biolegend 
 
anti-CD62L 
 
eFluor 605NC 
 
clone MEL-14; eBioscience 
 
anti-CD127 
 
PE 
 
clone A7R34; Biolegend 
 
anti–IFNγ 
 
Allophycocyanin 
 
clone XMG1.2; Biolegend 
 
anti–TNFα 
 
FITC 
 
clone MP6-XT22; Biolegend 
 
CD49d purified 
 
 
 
clone 37.51; eBioscience 
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CD28 purified 
 
 
 
clone R1-2; eBioscience 
 
anti-CD8 
 
eFluor 450 
 
clone 53-6.7, eBioscience 
 
anti-CD62L 
 
PE 
 
MEL-14, BD 
 
anti-CD44 
 
FITC 
 
IM7, BD 
 
Annexin V 
 
Allophycocyanin 
 
BD 
 
7AAD (7-Amino-
actinomycin D) 
 
(PerCP) 
 
 
Sigma-Aldrich 
 
2.6.3 Dextramer 
Allophycocyanin labelled MHC Dextramer, H-2Kb RALEYKNL (Immudex, Kopenhagen, 
DK) 
 
2.7 Materials and Equipment 
Accuri Cytometer BD (Franklin Lakes, NJ, USA) 
Beakers Nalgene (Rochester, NY, USA) 
Centrifuge Tubes for Blood 
Samples 
FisherBrand (Thermo Fisher Scientific, Waltham, 
MA, USA) 
Butterfly Needle Dispomed Witt (Gelnhausen, DE) 
Cell Culture Dishes Greiner Bio-One (Frickenhausen, DE) 
Cell Culture Flasks Thermo, nunc (Thermo Fisher Scientific, Waltham, 
MA, USA) 
Cell Culture Plates BD (Franklin Lakes, NJ, USA) 
Cell Scrapers TPP (St. Louis, MO, USA) 
Cell strainer BD (Franklin Lakes, NJ, USA) 
Centrifuges Thermo (Thermo Fisher Scientific, Waltham, MA, 
USA), eppendorf (Hamburg, DE) and sorvall 
(Thermo Fisher Scientific, Waltham, MA, USA) 
15 ml/ 50 ml Centrifugation Greiner Bio-One (Frickenhausen, DE) 
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Tubes 
Corex Tubes GENcompare (Brüssel, BE) 
Cryo Tubes Brand (Wertheim, DE) 
Cuvettes Sarstedt (Nümbrecht, DE) 
Douncer Kleinfeld (Gehrden, DE) 
Electrophoresis Systems Serva (Heidelberg, DE) and Biozym (Hessisch 
Oldendorf, DE) 
Folded Filter Schleicher & Schuell (Dassel, DE) 
Gene Pulser II Bio-Rad (München, DE) 
Gene Pulser Cuvette 0.2 cm Bio-Rad (München, DE) 
Incubators Thermo (Thermo Fisher Scientific, Waltham, MA, 
USA) and NuAire (Plymouth, MN, USA) 
Long Size Pipettes WU Mainz (Mainz, DE) 
LSRII BD (Franklin Lakes, NJ, USA) 
LSR Fortessa BD (Franklin Lakes, NJ, USA) 
Micro Tubes Biozym (Hessisch Oldendorf, DE) and Greiner Bio-
One (Frickenhausen, DE) 
Pipettes For Cell Culture Greiner Bio-One (Frickenhausen, DE) 
Pipette Tips STARLAB (Hamburg, DE) 
Plates for Cultivation of Bacteria Nerbe-plus (Winsen/Luhe, DE) 
Safety Work Bench Thermo (Thermo Fisher Scientific, Waltham, MA, 
USA) 
Scalpels Braun (Melsungen, DE) 
Small FACS Tubes Micronic (Lelystad, NE) 
Software CFlow Plus from BD, Version 1.0.227.4 
FlowJo from Tree Star (Ashland, OR, USA) 
Version 9.4 
FACSDiva from BD, Version 6.1 
GraphPad Prism from GraphPad (La Jolla, 
CA,USA), Version 5.04 
Vector NTI Advance from life technologies 
(Carlsbad, CA,USA), Version 11.0 
SpectroPhotometer ND-1000 peqlab biotechnologie (Erlangen, DE) 
SpectroPhotometer UltraSpec 
3100 pro 
GE Healthcare (Thermo Fisher Scientific, 
Waltham, MA, USA) 
Syringes Braun (Melsungen, DE) 
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Thermocycler life technologies (Carlsbad, CA,USA) 
Thermomixer Eppendorf (Hamburg, DE) 
Ultracentrifuge Thermo (Thermo Fisher Scientific, Waltham, MA, 
USA) 
Ultraviolet (UV) Transilluminator Biometra (Göttingen, DE) 
Waterbath GFL (Burgwedel, DE) 
 
2.8 Mice 
C57BL/6 Janvier (Le Genest Saint Isle, France) 
 
C57BL/6 R26Cre.ERT2 central breeding facility of the HZI, Braunschweig 
 
C57BL/6 
Rag2flox/floxxR26Cre.ERT2 
central breeding facility of the HZI, Braunschweig 
 
Balb/c CMV-Cre central breeding facility of the HZI, Braunschweig 
 
 
2.9 Mice Handling 
All animal experiments performed at HZI were performed in compliance with the 
German animal protection law (TierSchG BGBI S. 1105; 25.05.1998) and were 
approved by the responsible state office (Lower Saxony State Office of Consumer 
Protection and Food Safety). The mice were housed and handled in accordance with 
good animal practice as defined by FELASA and the national animal welfare body 
GV-SOLAS. If necessary the transgenic mice were genotyped as described in the 
appendix. 
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2.10 Cell Lines 
M2-10B4  CRL-197; American type culture collection 
ATCC, VA, USA 
NIH 3T3  CRL-1658; American type culture collection 
ATCC, VA, USA 
C57BL/6 MEFs 
 
 all primary cells have been isolated at HZI, 
Braunschweig 
Balb/c MEFs  all primary cells have been isolated at HZI, 
Braunschweig 
Balb/c CMV-Cre MEFs 
 
 all primary cells have been isolated at HZI, 
Braunschweig 
C57BL/6 R26Cre.ERT2 
MEFs 
 
 all primary cells have been isolated at HZI, 
Braunschweig 
 
2.11 Viruses 
The MCMV genome was previously cloned as a BAC [189], and the corresponding 
MCMV WT virus has been characterized in detail [190].  
The recombinant MCMV IE1/3flox was generated by 2-step BAC recombineering using 
the galactokinase (galK) selection, predominantly as described before [191] and in 
“Viral Mutagenesis” on page 38. The virus MCMV IE2SL was provided by Iryna 
Dekhtiarenko (HZI, Braunschweig) and described in Dekhtiarenko et al. [155]. 
 
2.12 Bacteria 
The E. coli strain which carries the MCMV BAC and has been used for the viral 
mutagenesis was described previously [191]. 
 
strain Genotype Phenotype 
SW102 mcrA ∆(mrr-hsdRMS-mcrBC) ∆lacX74 deoR endA1  
araD139 ∆(ara, leu) 7697 rpsL recA1 nupG  
ϕ80dlacZ∆M15 [λc1857 (cro-bioA)<>Tet] gal+ ∆galK 
Gal- 
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2.13 Molecular Biology 
 
2.13.1 Cultivation and Storage of Escherichia coli 
The E. coli cells were cultivated in LB medium [192]. The medium was supplemented 
with the appropriate antibiotic (final concentrations for different antibiotics see page 24) 
for bacteria, which contains plasmids or BACs with an antibiotic-resistance-cassette to 
sustain the selection pressure on the appropriate plasmid or BAC. For solid medium, 
1.5% agar was added to the liquid medium. The cells were incubated at 37°C whereas 
cells containing the strain SW102 were incubated at 32°C, on LB agar plates or as a 
liquid culture with shaking at 120 revolutions per minute (rpm). These rpm was used in 
all subsequent methods for cultivation of E. coli. 
For long term storage, the E. coli cells were incubated overnight (ON) in LB medium 
containing the appropriate antibiotic at a suitable temperature with shaking. 750 µl of 
the ON bacterial culture were mixed with 250 µl 80% Glycerol (3:1) in a cryo vial and 
stored at -70°C. 
 
2.13.2 Isolation of Plasmid-DNA from E. coli 
E. coli strains containing the desired plasmids were incubated ON in 5 ml LB medium 
and the appropriate antibiotic at 37°C, with shakin g. Isolation of plasmid DNA was 
performed using the QIAGEN Plasmid Mini Kit according to the manufacturer’s 
protocol. The concentration of DNA was determined photometrically at 260 nm with the 
SpectroPhotometer ND-1000. 
 
2.13.3 Isolation of BAC-DNA from E. coli 
E. coli strain SW102 containing the corresponding BAC was incubated ON in 5 ml 
LB medium with the appropriate antibiotics at 32°C with shaking. This starter culture 
was diluted in 250 ml LB-medium with the suitable antibiotics and incubated ON at 
32°C with shaking. For isolation of BAC DNA, the Qi agen Plasmid Maxi Kit (QIAGEN-
tip 500) with modified protocol was used. To isolate BAC DNA for restriction analysis, 
the Qiagen Large-Construct Kit was used. 
In brief, bacteria from the main culture were isolated and the pellet was re-suspended 
in P1 buffer by pipetting up and down. To lyse the cells, P2 lysis buffer was added and 
the suspension was mixed by gently inverting the tubes 20 times, to prevent shearing 
of the genomic DNA. The lysis was stopped after 5 minutes (min) by adding chilled 
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buffer P3. The suspension was mixed by gently inverting the tubes 20 times and 
incubated for 30 min on ice to precipitate the DNA. The proteins and cell debris were 
removed by two centrifugation steps. To prevent clogging of the QIAGEN-tips, the 
supernatant (SN) was filtered over a prewetted and folded filter into new tubes. The 
DNA was precipitated with 0.7 volume of Isopropanol and centrifuged at 20000 g for 
30 min at 4°C. Before using the QIAGEN-tip, it was equilibrated with QBT buffer. The 
DNA pellet was re-dissolved in 500 µl TE-buffer and re-suspended in 11.5 ml 
QBT buffer. To separate the BAC DNA from the genomic DNA, the SN was added to 
the column and washed twice with QC buffer. To elute the DNA from the column into 
Corex tubes, prewarmed (65°C) QF buffer was added. To increase the yield of DNA, a 
second precipitation step was performed. The eluate was centrifuged at 15000 g for 
30 min at 4°C and then was washed with 70% Ethanol (EtOH). To remove the EtOH 
from the DNA, the pellet was air-dried for 5 - 10 min. The DNA was re-suspended in 
50 - 150 µl TE buffer ON and stored at 4°C. 
The concentration of the DNA was determined by photometric analysis at 260 nm in a 
SpectroPhotometer ND-1000.  
 
2.13.4 Isolation of Genomic DNA from Mouse Cells for Genotyping 
To genotype the transgenic mice, a tip of the mouse tail was cut and lysed in 498 µl 
lysis buffer and 2,5 µl Proteinase K at 56°C with s haking at 800 rpm for at least 6 hours 
(h). To inactivate the Proteinase K, the lysate was incubated for 5 min at 95°C. To 
remove proteins and cell debris a centrifugation step at 16000 g for 5 min was 
performed in a table microcentrifuge. The SN, containing the DNA, was transferred to a 
new tube and the DNA was purified by Isopropanol/EtOH-precipitation. To this end, 
500 µl Isopropanol were added to the lysate and tubes were inverted slowly until both 
phases were mixed. After centrifugation at 16000 g for 10 min, the pellet was washed 
with 500 µl 70% EtOH, incubated for 10 min at room temperature (RT) and centrifuged 
at 16000 g for 5 min. The pellet was dried at RT or at 37°C until all EtOH was 
evaporated. The DNA was re-suspended in 200 µl TE-buffer at 37°C for 10 min with 
shaking at 450 rpm. The genomic DNA was stored at 4°C. 
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2.13.5 Polymerase Chain Reaction (PCR) 
The PCR was used to amplify particular DNA fragments [193], [194]. The reactions 
were done with a thermo stable polymerase and oligonucleotides (primers). The 
primers were used in a final concentration of 1 pmol in reaction buffer according to the 
manufacturer's instructions of the used polymerase. The nature and duration of the 
temperature profile was determined by the manufacturer, the used primers and the 
template. The approaches and programs which were used in this thesis can be found 
in the appendix. To verify the amplified fragments, the PCR products were applied 
together with a suitable DNA size standard on a 1% agarose gel, which was prepared 
with 0.5 x TBE buffer. 
 
2.13.6 Enzymatic Digestion of DNA with Restriction Endonucleases 
For analytical restriction reactions 400 ng of plasmid DNA or 0.75 µg of BAC DNA were 
digested with 2 units of the restriction enzyme. The sample, containing plasmid DNA, 
was incubated in a volume of 10 µl for 1 h at 37°C.  The sample, containing BAC DNA, 
was incubated in a volume of 40 µl for 3 h at 37°C.  The reaction buffers were used as 
specified by the manufacturer. For the restriction of preparative amounts of DNA, larger 
volumes and amounts of enzymes were used. 
 
2.13.7 Separation of DNA in an Agarose Gel 
For the agarose gel 0.5 x TBE buffer was boiled with 1% agarose. For gels, analysing 
BAC DNA restrictions with, 0.8% agarose were used. After cooling down, 0.005% 
GelRed was added to the viscous solution which was poured into the gel chamber. As 
running buffer 0.5 x TBE buffer was used. If necessary, a loading buffer was added 1:6 
to the DNA sample before separation. The electrophoretic separation was done at 
135 volt (V) DC (Direct Current) for 25 - 35 min for PCR products and at 80 V DC for 
15 - 25 h to separate restriction fragments of BAC DNA. The DNA was visualised by 
irradiating the gel with UV light λ = 312/319 nm. To determine the size of the DNA 
fragments the "™ GeneRuler 1 kb DNA Ladder" or the "™ GeneRuler 1 kb Plus DNA 
Ladder" were used as size standards. 
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2.13.8 Isolation of DNA from an Agarose Gel 
The DNA, stained with GelRed, was detected by a UV transilluminator at 
λ = 312/319 nm. The gel fragment, containing the desired band, was cut out with a 
scalpel and transferred into a 1.5 ml tube. The isolation of the DNA fragments was 
done with the QIAquick Gel Extraction Kit, according to the manufacturers’ protocol. 
The DNA was eluted with 15 µl elution buffer and stored at -20 ° C. 
 
2.13.9 DNA Sequencing 
The sequencing of the recombinant MCMV IE1/3flox BAC and the PCR products was 
performed by the group “Genomanalytik” of Robert Geffers at the HZI. 
 
2.13.10 Preparation of Electro-Competent E.coli 
Electro-competence of E. coli cells requires that they are in the growing phase and 
clean of salt. Therefore a starter culture was done by growing bacteria ON in a 5 ml 
LB culture with the appropriate antibiotics at 37°C  with shaking. 4 ml of the starter 
culture was diluted in 200 ml LB medium with the appropriate antibiotics and incubated 
for 3 - 4 h at 32°C with shaking. The optical densi ty (OD) at 600 nm was measured with 
the UltraSpec 3100 pro at regular time intervals, until an OD of 0.5 – 0.6 was reached. 
The bacteria were pelleted at 2500 – 3500 g for 10 min at 1°C. To remove the salt from 
the bacteria, they were washed with 10% Glycerol. The following steps were performed 
on ice. The pellet was re-suspended in 10 ml chilled 10% Glycerol, which was added to 
the pellet with a chilled and sterile plastic pipette. The bacteria were pelleted at 
2500 - 3500 g for 10 min at 1°C. The washing steps were repeated two times. After the 
last washing step the bacteria were re-suspended in the fluid from the sides of the 
tubes which reaches the bottom of the beaker. The bacteria were either aliquoted at 
60 µl in chilled tubes or used immediately for transformation. For storage at -70°C, they 
were shock frozen in liquid N2. 
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2.13.1 Transformation of E.coli with Electroporation 
To transform DNA into E. coli, the bacteria cell membranes were made permeable for 
molecules of high molecular weight by short electrical pulses of high field strength. 
Therefore, electro competent bacteria cells were thawed on ice, up to 12 µl PCR 
product was added, mixed carefully and incubated for 2 min on ice. During this time, 
the DNA could adhere to the bacterial cells. The mixture was transferred into a chilled 
cuvette without air bubbles. For the electroporation the "Bio-Rad gene pulser II" was 
used. 
The electroporation was done for 3.5 – 5 milliseconds (msec) with: 
 Capacity of the condenser = 25 µF 
 Electric tension U = 2.5 kV 
 Resistance R = 200 Ω 
Immediately after electroporation the bacterial cells were transferred to a glass tube 
containing 1 ml LB medium without antibiotics. The cells were incubated for 1 h at 37°C 
with shaking to give them time to produce resistance to the selective antibiotics. From 
the bacterial culture 10 µl, 100 µl and 200 µl were seeded on LB agar plates 
supplemented with the appropriate antibiotic and incubated ON at 37°C until bacterial 
colonies have been formed. 
 
2.13.2 Viral Mutagenesis: Recombinant BAC MCMV IE1/3flox 
The recombinant virus MCMV IE1/3flox was generated using the galK 
positive/counterselection described by Warming et al. [191], with modifications 
described by Dölken et al. [195]. 
For the recombinant MCMV, the BAC “MCMV-C3X m129repair” transformed in E. coli 
strain SW102 was used [191]. The bacterial strain SW102 contains a stable integrated 
defective λ prophage. From its strong promoter pL, the genes exo, bet and gam are 
expressed under the control of the temperature-sensitive repressor c1857. These 
genes are responsible for the recombination of linear fragments into the BAC genome 
[196], [197], but are not expressed at 32°C. To act ivate them, an incubation step at 
42°C for at least 15 min is necessary. Furthermore the SW102 cells contain the 
galactose operon, except for the galactokinase gene for the galK, and hence cannot 
metabolise galactose, unless the galK is expressed in trans. 
In the recombinant MCMV IE1/3flox the ORFs of the immediate-early genes ie1 and ie3 
were flanked by two loxP sequences (Figure 8), to allow its target, the enzyme Cre 
recombinase, to recombine the MCMV genome.  
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13 bp                     8 bp                     13 bp 
ATAACTTCGTATA – ATGTATGC – TATACGAAGTTAT 
 
Figure 8 Sequence of the loxP site. 
LoxP is a DNA sequence derived from the bacteriophage P1, which is composed of 34 bp. It 
consists of an asymmetric 8 bp sequence which is flanked by two palindromic sequences of 
13 bp. 
 
The first loxP sequence was inserted between the stop-codon of ie3 and its poly(A) tail, 
replacing the nucleotides 177965 – 177974 [37], where it does not affect the correct 
reading of the genes. For the second loxP sequence, the non-coding Exon 1 of ie1/3 
was chosen, replacing the nucleotides 182837 – 182846 [37] (Figure 9). The location is 
far enough away from the start-codon, not to disturb the correct reading of the 
RNA-polymerase or of the ribosome and on the other hand the promoter-enhancer 
structure of ie1/3 is not impaired. Another advantage of this strategy is that the 
recombination does not remove the promoter-enhancer from the viral genome, and 
therefore the genes ie1 and ie3 cannot be expressed ectopically. 
 
Ex12Ex5 Ex4 Ex3
ie1/3
P1/3-E
TATA-BoxpolyA-Signal
Stop-Codon Start-Codon
loxP loxP
 
 
Figure 9 Overview about the modified ie1/3 locus of MCMV IE1/3flox. 
The left loxP sequence was inserted into the non-coding Exon 1 of ie1/3. The right loxP 
sequence was inserted in the Exon 5 between the stop-codon and the poly(A)-tail of ie3. 
 
In a first step, a linear PCR product was generated in a reaction with the pGPS/galKn 
plasmid [195] as template. The galK/Kn cassette, containing the galK and the Kan 
genes, was amplified with primers which carried at their 5’ end 50 bp homology 
sequences to the site in the viral genome at which the loxP sequence was introduced 
and homologies to the galKn plasmid at their 3’ end. The primers P9 and P11 were 
used to amplify the galK/Kn cassette for the insertion between the stop-codon of ie3 
and the poly(A) tail, and the primers P43 and P45 were used to amplify the galK/Kn 
cassette for the insertion into the non-coding Exon 1 of ie1/3. The PCR programs and 
reagents used are shown in the appendix. To remove the template DNA from the PCR 
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reactions, a digestion with 20 units of the enzyme DpnI was performed at 37°C ON, 
which was followed by a purification step, in which the PCR product was extracted from 
a 1% agarose gel (see page 37). The transformation was done into electro competent 
SW102 bacteria containing the WT BAC as described above (see page 37), with the 
following modifications. In all steps, the bacterial cells were incubated at 32°C instead 
of 37°C. To activate the genes exo, bet and gam, the bacterial cells were incubated at 
42°C for 15 min with shaking prior to induce electr o-competence (page 37). The 
electro-competent E. coli were transformed with the PCR products according to the 
protocol on page 38. 10 µl, 100 µl and 500 µl of the transformed bacterial culture were 
seeded on Kn/CAM agar plates. Clones that integrated the product were selected from 
Kn/CAM plates after 1 – 2 days of incubation and confirmed by monitoring on 
McConkey agar plates, restriction pattern analysis and sequencing. 
In a second mutagenesis step, a PCR product carrying the loxP sequence, flanked by 
MCMV sequences, was introduced into the MCMV BAC by homologous recombination 
and metabolic selection on minimal 2-deoxy-galactose plates. The construct for 
introducing the loxP sequence into the 3’ end of ie3, was synthesised by GENEART 
(Regensburg, DE) and the primers P18 and P19 were used to amplify the construct. 
The construct, used to introduce the loxP sequence into the Exon 1 of ie1/3, was 
synthesised by Eurofins MWG Operon and the primers P46 and P47 were used to 
amplify the construct. The PCR programs and reagents used can be found in the 
appendix. The obtained PCR products were handled and transformed into the E. coli 
as described above, with the following modifications. After transformation, the bacteria 
were incubated in 10 ml LB medium for 4.5 h at 32°C  and washed twice with 
1 x M9 medium to get rid of the LB medium. 1 ml of the bacterial culture was 
centrifuged at 16000 g for 15 seconds (sec) at RT and re-suspended in 1 ml 
1 x M9 medium. 10 µl, 100 µl and 500 µl were seeded on Minimal plates containing 
DOG and CAM. Clones that integrated the product were selected from the Minimal 
plates after 4 – 5 days of incubation and confirmed by restriction pattern analysis and 
sequencing. 
The correct insertion of the loxP sites into the BAC and the absence of undesired 
mutations were confirmed by sequencing of the entire BAC. The newly generated BAC 
was used for transfection of murine embryonic fibroblasts (MEFs) to generate 
infectious viral progeny (see page 43). 
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Figure 10 Overview galK/Kn selection scheme. 
In the first step, the galK/Kn cassette, flanked with homologies to the target site of MCMV BAC, 
was introduced. The selection on bacteria, which were positive for the galK/Kn cassette, was 
done by using MacConkey agar plates supplemented with kanamycin and galactose. In the 
second step, the construct, which carried the desired mutation and was flanked with the same 
homologies as in the first step, was inserted. The selection was performed on minimal plates, 
supplemented with DOG and glycerol for bacteria which were negative for the galK, but positive 
for the desired mutation. (modified from [191]) 
 
2.14 Cell Culture 
 
2.14.1 Cultivation of Mammalian Cells 
The cells were kept in a cell culture incubator at 37°C and with 5% CO 2. For most of 
the cell types, the used cell culture medium was DMEM supplemented with 10% FCS, 
1% Glutamine and 1% Penicillin/Streptomycin (suppl. DMEM). 
To maintain the cells, they were trypsinised and passaged on new plates. The medium 
was removed from the confluent cells by vacuum aspiration, followed by a wash with 
PBS to get rid of residual medium. To detach the cells from the plastic surface, they 
were trypsinised at 37°C for approximately 5 min. T he reaction was stopped by adding 
medium containing 10% FCS. The medium was removed from the cells by 
centrifugation and then the cells were re-suspended in an appropriate amount of 
medium and seeded to a new flask or dish. 
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2.14.2 Storage of Mammalian Cells 
Cells were incubated either on a 14.5 cm ∅ dish or a T175 flask until they reached 
80 - 90% confluence. The freezing medium, containing 10% DMSO and 90% FCS was 
kept on ice all the time. The cells were washed once with PBS, to remove medium and 
FCS. To detach cells from the surface, there were treated with trypsin and incubated at 
37°C for approximately 5 min. To inactivate the try psin, medium with 10% FCS was 
given to the cells and the suspension was collected in a blue cap tube. The trypsin was 
removed from the cells by centrifugation and the cells were re-suspended in freezing 
medium (3 ml freezing medium per dish or flask). The cells were aliquoted to 1 ml in 
pre-chilled cryo vials. To freeze the cells slowly, they were put in a container, which 
was surrounded with Isopropanol and frozen at -20°C  for 2 days, before they were 
frozen in liquid nitrogen. 
 
2.14.3 Preparation of Mouse Embryonic Fibroblasts (MEFs) 
MEFs were prepared as described before [198] with some modifications. At day 13 - 15 
after the positive plaque-check, the pregnant mouse was sacrificed by CO2 asphyxia, 
sterilized with EtOH and fixed on a Styrofoam board. The abdomen was opened with 
sterile instruments and the uterus with the foetuses was extracted and transferred to a 
dish with PBS. The foetuses were isolated from amnion and placenta and transferred 
to a clean dish with PBS to wash away the blood and remains of other tissue. From 
liver and intestine as much as possible was removed and the foetuses were transferred 
to another dish without PBS to mince them into very small bits using scalpels. 10 ml 
trypsin per foetus were added and up to 7 foetuses were transferred to an Erlenmeyer 
beaker filled with beads of glass. The cells were separated by stirring the cell 
suspension on a magnetic stirrer with a magnetic bar for 1 h at 37°C, which moves the 
beads around, but not too vigorously. Then, an equal volume of suppl. DMEM was 
added to the cells to make the suspension less viscous, upon which the cells were 
transferred to 50 ml tubes. To get rid of the trypsin, the cells were pelleted by 
centrifugation at 314 g for 10 min at RT. The SN was removed carefully and the cells 
were re-suspended in suppl. DMEM. To get rid of big tissues bits the cells were passed 
through a 100 µm cell strainer and pooled afterwards. The cells were counted in a 
Neubauer’s chamber and cultured in T175 flasks with an amount of 107 cells per flask 
using suppl. DMEM. After one day of incubation, the cells were washed twice with PBS 
and fresh suppl. DMEM was added. When the cells reached 90% of confluence, they 
were expanded 1/3 on T175 flasks. To detach the cells from the surface, there were 
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treated with trypsin and incubated for approximately 5 min at 37°C. To inactivate the 
trypsin, suppl. DMEM was given to the cells and the suspension was collected in a 
50 ml tube. To remove the trypsin from the cells, there were centrifuged for 5 min at 
314 g. The SN was discarded and the cells were re-suspended in a proper amount of 
suppl. DMEM and cultured in T175 flasks. The cells were incubated until they reached 
80% of confluence, in order to be able to freeze them in the growing phase. The 
freezing medium, containing 10% DMSO and 90% FCS was kept on ice all the time. 
The cells were washed once with PBS, to remove medium and FCS. The cells were 
detached from the surface like described above. The pelleted cells were re-suspended 
in freezing medium (3 ml freezing medium per T175 flask). The cells were aliquoted to 
1 ml in pre-chilled cryo vials. To freeze the cells slowly, they were put in a container, 
which was surrounded with Isopropanol and frozen at -20°C for 2 days, before they 
were frozen in liquid nitrogen. 
 
2.14.4 Generation of MCMV from BAC DNA by Transfection of Mammalian 
Cells 
To generate MCMV from BAC DNA, the DNA was transfected into mammalian cells. 
For the transfection, freshly prepared MEFs were used. One day before transfection 
the MEFs were seeded on a 6-Well plate, with 6 x 105 cells per well in suppl. DMEM. 
On the day of transfection they were 50 - 60% confluent. 
Transfection was performed with the Fugene HD Transfection Reagent, MCMV BAC 
DNA and Opti-MEM I Reduced Serum Medium, all warmed to RT prior to the 
procedure beginning. 2 µg of the BAC DNA (260/280 nm: ca. 1.8) were mixed with 
Opti-MEM in a total volume of 100 µl. 4 - 8 µl FUGENE Reagent were vortexed and 
added to the diluted DNA without touching the plastic. The solution was mixed by 
pipetting up and down. To allow the FUGENE Reagent to attach to the DNA, it was 
incubated at RT for at least 15 min. Transfection was optimised by replacing the 
standard cell culture medium with DMEM and 10% FCS, but without antibiotics. 100 µl 
of the transfection complex was added to the cells in a drop-wise manner and swirled, 
to allow its distribution over the entire plate surface. Cells were incubated with the 
complex at 37°C for 5 h, upon which the medium with  the transfection complex was 
replaced with fresh suppl. DMEM and incubated for 48 - 72 h. To allow cells to grow, 
they were split into a T25 flask. 
The transcription of viral genes initiated from the BAC DNA and after a week later, virus 
growth could be observed by the presence of viral plaques, consisting of a clearance in 
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the cell monolayer surrounded by rounded cells. Cell rounding was caused by virus 
induced morphological changes in the cell, which are also termed “cytopathic effects” 
[199]. The newly generated viruses initially still carried the BAC vector in their genome. 
The BAC vector allows the BAC DNA replication in E. coli and carries an antibiotic 
selection marker, ensuring that only cells carrying the BAC, replicate in the presence of 
CAM. Its presence in the replicating virus results in a genome over length, which 
impairs DNA packaging into the virion and thus deters viral replication. Hence, in order 
to obtain a virus which is modified as little as possible, the vector was removed. Since 
the vector is flanked by homologous sequences of the MCMV genome, the 
recombination of homologous sequences can lead to the excision of the BAC 
sequence. Selection pressure favours the viruses which have lost the BAC. Therefore, 
consecutive passaging of the reactivated virus results in an enrichment of the MCMV 
WT genome which have lost the BAC [26]. 
 
1. passage
2. passage
3. passage
4. passage
5. passage
Transfection
ReagentMCMVBAC
 
 
Figure 11 Generation of MCMV by transfection and passaging. 
MEFs were transfected with the MCMV BAC DNA in presence of a transfection reagent. To get 
rid of the BAC vector, the virus was passaged five times on M2-10B4 cells. 
 
To get rid of the BAC cassette, the virus was passaged five times. After the transfected 
cells showed 100% cytopathic effects, SN containing the MCMV virus was used to 
infect a new monolayer of mouse bone marrow stromal cells (M2-10B4 cells). Thus, 
1 ml SN of the infected MEFs was used to infect one T25 flask of M2-10B4 cells. When 
these cells were lysed, 1 ml SN was used to infect another T25 flask of M2-10B4 cells, 
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which was pursuit until the 5th passage. Then, the SN of the completely infected and 
lysed cells was used for preparing a virus stock (Figure 11). 
 
2.14.5 Preparation of Virus Stock 
Viruses were propagated as described before [200] with some modifications. 
Two 15 cm plates with M2-10B4 cells at 30 - 50% confluence were each infected with 
1 ml SN from passage 5 of virus after transfection. After 4 - 5 days, cells and SN were 
harvested. The suspension was used directly to infect cells for the virus stock or it was 
frozen at -70°C before usage. 
M2-10B4 cells from fourteen 15 cm plates were 90 - 100% confluent, when they were 
used to make the virus stock. The medium was removed from the plates and the cells 
were washed with PBS. To detach the cells, they were incubated in the presence of 
trypsin at 37°C for approximately 5 min. To stop th e reaction, suppl. DMEM was added 
and the cells were transferred to four 50 ml centrifuge tubes and centrifuged at 314 g 
for 5 min at RT. Afterwards the SN was removed and the cells were re-suspended in 
10 ml suppl. DMEM per centrifuge tube. The cells from the centrifuge tubes were 
transferred in two 500 ml bottles and medium was added to a volume of 400 ml per 
bottle. The suspension from the two plates infected in advance was added and mixed 
by inverting the flasks. The cells were seeded to forty 15 cm plates (20 ml cell 
suspension per plate) and incubated for 4 – 5 days. 
The virus was harvested once most of the cells were lysed and detached from the 
bottom. Therefore, most of the SN was transferred to 400 ml centrifuge bottles on ice, 
but 3 – 4 ml was left on the plates. The cells were scraped from the plates with a cell 
scraper and collected with the medium left on the plate. The cells were pelleted by 
centrifugation at 5800 g for 15 min at 4°C. The SN was collected and stored on ice. To 
obtain virus from the cells the pellet was dounced in 4 ml suppl. DMEM in prechilled 
7 ml douncers. To remove the cell debris, the re-suspended pellet was centrifuged at 
17000 g for 10 min at 4°C. The SN, containing the v irus, was added to the SN obtained 
in the first centrifugation round, and the virus was pelleted by centrifugation at 27600 g 
for 3.5 h at 4°C. 4 ml of suppl. DMEM was added to the pellet and it was softened on 
ice ON at 4°C, before douncing in a prechilled doun cer. To purify the virus, the re-
suspended pellet was put carefully on top of 10 ml cold 15% sucrose-VSB. The 
suspension was overlayed with VSB without mixing the layers. The virus was obtained 
by centrifugation at 72000 g for 1 h and 20 min at 4°C in an Ultracentrifuge. To soften 
the pellet, it was incubated in 1.2 ml VSB ON on ice at 4°C, before douncing in a 
prechilled douncer. The suspension was transferred to a 2 ml reaction tube and 
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centrifuged at 1200 g for 2 min at 4°C. The SN from  that step was centrifuged again 
and the SN from the last step was aliquoted in 0.5 ml micro tubes at 30 – 50 µl and 
stored at -70°C until quantification. 
 
2.14.6 In Vitro Infection 
Monolayers of NIH3T3 cells were infected in 24-well plates with a multiplicity of 
infection (MOI) of 0.1. The cells were incubated with the virus for 1 h and 37°C and the 
plates were stirred gently from time to time. From one well, the inoculum was removed 
and stored at -70°C. From the other wells the mediu m was removed and the cells were 
washed once with PBS, before 1 ml suppl. DMEM was added to each well. The cells 
were incubated at 37°C until the end of experiment.  Every 24 h the SN was collected 
from one well for 6 days and stored at -70°C. The e xperiment was done in triplicate and 
the virus in the SNs was quantified on MEFs. 
 
2.14.7 Infectious Virus Quantification 
Tissue culture SN or virus stocks were titrated on MEFs by plaque assay [39] with 
modifications described previously [169]. 
The titration was done on primary MEFs, whose passage was not higher than 4 at the 
time of titration. The cells were cultivated in 10 cm plates in suppl. DMEM and when 
they reached 100% confluence, the cells were seeded on two 48-well plates and 
incubated at 37°C ON. The virus was diluted from 10 -1 to 10-9 in DMEM supplemented 
with 5% FCS on ice. Then the medium from the MEFs was removed and in triplicate 
wells replaced with 200 µl/well of the diluted virus (dilutions 10-2 to 10-9). The plates 
were incubated for 1 h at 37°C. Afterwards, the vir us dilutions were removed from the 
cells and replaced with 500 µl/well prewarmed carboximethylcellulose and further 
incubated at 37°C for 4 days before the read out. 
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2.14.8 In Vitro Recombination of MCMV IE1/3flox 
MEFs expressing inducible Cre.ERT2 (derived from transgenic C57BL/6 R26Cre.ERT2 
mice) were seeded in 10 cm plates at 30 - 35% confluence and incubated for 48 h in 
presence of 1 µM Tam at 37°C. Cells from one 10 cm plate were transferred to 6 Wells 
of a 12-well plate and infected with MCMV IE1/3flox at MOI 0.1. After incubating the 
cells for additional 48 h, the SN was harvested and the virus in 15 µl of SN was used 
as template to analyse the ie1/3 gene locus for recombination by PCR with the primers 
P18 and P47. The programs and reagents used can be found in the appendix. 
 
2.14.9 IFNβ-Induced Latency and Virus Reactivation 
20.000 CMV-Cre MEFs/well (MEFs, expressing a Cre recombinase from the transgenic 
mice Balb/c CMV-Cre) were incubated in 96-well plates for 24 h in the presence of 500 
or 100 units of IFNβ. The cells were washed once with PBS and infected with a 
MOI 0.001 or 0.0001 with MCMV WT or MCMV IE1/3flox. The medium containing the 
virus was removed after 1 h at 37°C and replaced wi th suppl. DMEM containing IFNβ 
(suppl. DMEM without IFNβ in control wells) and incubated for 7 days. The medium 
containing the IFNβ was replaced every 2 – 3 days with fresh medium + IFNβ. At 
7 days post infection (dpi) the IFNβ containing medium was replaced with normal 
medium in selected wells and the cells were incubated for additional 21 days. The wells 
were monitored for infectious plaques throughout the experiment. 
 
2.15 Immunological Biology 
 
2.15.1 In Vivo Infection 
Mice were infected i.p. with a total volume of 200 µl of purified, tissue culture-derived 
MCMV diluted in PBS. The amount of input virus depended on the mouse strain: 
2 x 105 plaque forming unit (pfu) were used to infect mice on the Balb/c background 
and 1 x 106 pfu were used for mice on C57BL/6 background. 
 
2.15.2 Oral Administration of Tamoxifen 
Mice were fed with pellets, containing 400 mg/kg Tam CRD Tam400/CreER from Teklad 
for 2 - 4 weeks, depending on the experiment. 
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2.15.3 Virus Quantification in Organ Samples 
Mice were euthanized by CO2 asphyxia. The organs were dissected under sterile 
conditions and stored in 2 ml reaction tubes containing 1 ml RPMI at -70°C until 
titration. If the whole organ was not collected, the reaction tubes containing 1 ml RPMI 
were weighed before and after the tissue collection. 
The organs were titrated on MEFs. Cells from 10 cm plates with 100% confluence were 
seeded on two 48-well plates and incubated ON at 37°C. The organs were thawed on 
ice, homogenised on 100 µm-pore-size cell strainers and diluted in 5 ml RPMI. The 
dilutions of 1:10, 1:100 and 1:1000 were done in a total volume of 500 µl suppl. DMEM 
with 5% FCS. Then, the medium was removed and replaced with 200 µl/well of the 
homogenate dilutions. To allow the virus to reach the MEFs, the plates were 
centrifuged for 30 min in swing out buckets at 690 g, before they were incubated for 
additional 30 min at 37°C. Afterwards, the homogena te dilutions were removed from 
the cells and replaced with 500 µl/well of prewarmed carboximethylcellulose and further 
incubated at 37°C for 4 days before the read out. 
 
2.15.4 Peripheral Blood and Spleen Collection and Processing 
Mice were anesthetized with Isofluran, before up to 150 µl blood were acquired from 
the retrobulbar venous plexus and diluted in 300 µl heparin in HBSS (2 units/ml). The 
blood samples were centrifuged and the erythrocytes were removed by brief osmotic 
shock lysis. Therefore, the tube was held on a vortex while 9 ml deionised water 
(dH2O) were added, which was immediately followed by slow addition of 3 ml 4 x PBS 
to make the solution isotonic and stop the lysis. The tubes with the cells were kept on 
the vortex all of time, to ensure that the cells swirl the whole time. The samples were 
centrifuged again, but this time the SN was not removed completely. The cells were re-
suspended in the rest of the SN (~ 100 µl) and transferred to a 96-well plate. The cells 
were pelleted by centrifugation and the excess fluid was removed by flicking the plate. 
Cells were detached from the bottom by briefly vortexing the plate and a second 
erythrocyte lysis was performed. 150 µl H2O were added to the samples, followed by 
an addition of 50 µl 4 x PBS to stop the lysis. The plates were centrifuged, the excess 
volume flicked off and the cells used for fluorescent staining or peptide stimulation (see 
chapters 2.15.6 to 2.15.9). 
To isolate splenic lymphocytes, mice were euthanized by CO2 asphyxia and the spleen 
was stored in 2 ml tubes with 1 ml RPMI on ice until usage. The spleen was 
homogenized on 100 µm-pore-size cell strainers and diluted in 5 ml RPMI. The 
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erythrocytes were removed from the spleen samples by ACK lysis. The ACK buffer was 
added to the splenocytes and incubated for 2 min at RT, to allow the erythrocytes to 
lyse. The reaction was stopped by adding 2 volumes RPMI, supplemented with 
10% FCS. The ACK buffer was removed by centrifugation and the splenocytes were 
re-suspended in 1 ml RPMI. The cells were counted using the Neubauer’s chamber 
and 2 – 5 x 106 cells were taken for further analysis. 
 
2.15.5 In Vitro Peptide Stimulation 
Blood lymphocytes were obtained as described in chapter 2.15.4, on page 48. After 
two washing steps with FACS buffer, the cells were stimulated in a 96-well plate for 1 h 
at 37°C with 1 µg/ml of the peptide, together with 0.25 µl of each CD28 and CD49d in a 
total volume of 100 µl RPMI (supplemented with 10% FCS). One hour later, Brefeldin A 
(10 µg/ml) was added and cells were incubated in the same conditions as above for 
additional 5 h. The cells were washed twice with FACS buffer and then used to stain 
against the surface marker. 
 
2.15.6 Antibody Staining for Flow Cytometry 
Surface markers on cells were stained according to the manufacture’s protocol in a 
total volume of 50 µl FACS buffer for 30 min at 4°C  in darkness, followed by two 
washing steps with FACS buffer. The stained cells were either used for intracellular 
cytokine staining (ICCS) or direct acquisition in an Accuri, in an LSRII, or in an 
Fortessa apparatus in a total volume of 50 – 100 µl FACS buffer. 
For ICCS, the cells were first stimulated with the desired peptides (see page 49, 
chapter “In Vitro Peptide Stimulation”) and then stained for the desired surface 
markers. After the surface markers were stained with fluorescent antibodies, the cells 
were fixed with 100 µl IC Fixation buffer at 4°C fo r 5 min, which was followed by 3 min 
permeabilisation with 100 µl permeabilisation buffer at 4°C. The cells were washed 
once with 200 µl permeabilisation buffer and incubated for 30 min at 4°C with anti-IFN γ 
antibody (Ab) and anti-TNFα Ab in a total volume of 50 µl permeabilisation buffer. 
Afterwards, the cells were washed twice in permeabilisation buffer and re-suspended in 
50 – 100 µl FACS buffer for acquisition. Peptide stimulated cells showed a better signal 
to noise ratio by IFNγ responses; thus, we focused on IFNγ as our readout system. 
Antigen-specific responses were discriminated from background noise by subtracting 
IFNγ responses in unstimulated controls from IFNγ values observed in peptide-
stimulated samples. The cytometric results were analyzed with the FlowJo software. 
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2.15.7 IE3-Dextramer Staining for Flow Cytometry 
The cells, derived from blood, were stained with the IE3-Dextramer prior to the surface 
marker staining. The peptide RALEYKNL, which is fused to the MHC proteins on the 
Dextramer backbone, was derived from the IE3 protein. 
After cell isolation and lysis of the erythrocytes, the cells were washed two times with 
FACS buffer, prior to the staining with 3 µl of the IE3-Dextramer in a total volume of 
30 µl FACS buffer for 15 min at RT in darkness. The surface marker staining with the 
desired antibodies was done according to the manufacturers’ protocol in a total volume 
of 20 µl FACS buffer. These 20 µl were added on top of the 30 µl IE3-Detramer 
staining solution and incubated for additional 20 min at 4°C in darkness. The cells were 
washed two times with FACS buffer and re-suspended in 50 – 100 µl FACS buffer for 
acquisition in a flow cytometer within 2 h after staining. 
 
2.15.8 Annexin V and 7AAD Staining 
Splenocytes were harvested as described in chapter 2.15.4 on page 48. 
4 x 106 splenocytes were used for the apoptosis staining. The cells were washed twice 
with PBS and incubated with a Live/Dead marker for 30 min at 4°C. The cells were 
washed with PBS and stained with CD8 – eFluor 450, CD62L – PE and CD44 – FITC 
for 15 min at 4°C. After an additional washing step  with PBS, the cells were re-
suspended in 250 µl binding buffer, before 5 µl Annexin V – APC and 2.5 µl 
7AAD - PerCP were added and then incubated for 15 min at RT in the darkness. 250 µl 
binding buffer was added to the staining mix and the cells were acquired at a flow 
cytometer. 
 
2.15.9 Counting Cell Populations in Absolute Terms 
Cells were either counted in the Neubauer’s chamber under a light microscope or with 
an Accuri flow cytometer. Therefore the cells were re-suspended in 100 µl FACS buffer 
from which 50 µl was acquired with an Accuri cytometer. For both methods the number 
of cells was calculated per ml. 
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2.15.10 Compensation with Single Stainings 
For an accurate analysis of data, obtained by flow cytometry (FCM), the different 
fluorescent labels were mutually compensated. Therefore single-stained compensation 
beads (CompBeads) or splenocytes were used prior to each cell acquisition. 
From a suspension, containing negative control CompBeads and anti-Rat and anti-
Hamster CompBeads, 100 µl were added to as many wells in the 96-well plate as the 
number of antibodies in the staining panel, plus an extra well for the unstained control. 
Individual antibodies from the panel were added to the CompBeads and incubated for 
30 min at 4°C in darkness. After the incubation tim e, the CompBeads were washed 
twice with FACS buffer, re-suspended in 100 µl FACS buffer and analysed with a flow 
cytometer. To perform the compensation with Splenocytes, 106 cells were used per 
single staining. 
 
2.16 Software and Statistical Analysis 
Samples were acquired in LSRII and Fortessa cytometers fitted with the FACSDiva 
software (BD, version 6.1). For further analysis, Flowjo software (Tree Star, version 
9.4) was used. Samples acquired at the Accuri cytometer were analysed by CFlow 
software (BD, version 1.0.227.4). 
Statistical analyses were performed with GraphPad Prism software (GraphPad, version 
5.04) and the Mann-Whitney U test (two-tailed) was used for comparisons between two 
groups. 
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3 Results 
In this work, the influence of persistent gene expression during latency on the 
maintenance of MI was analysed. Therefore, a conditional knock-out of the MCMV 
genes ie1/3, which are known to induce MI, was performed in vivo using the Cre/loxP 
system. The genes ie1/3 were flanked by loxP sequences and mice expressing 
ubiquitously an inducible Cre recombinase (Cre.ERT2) were infected. The knock-out 
was induced at several months post infection (p.i.) by feeding mice with Tam. The 
effect of the knock-out on the MI was analysed by monitoring the accumulation of 
IE3-specific CD8+ T cells throughout the experiment. However, unexpected results 
related to the toxic effect of Cre.ERT2 impaired the original plan. Thus the research 
goals were modified to investigate the effect of activated Cre.ERT2 on TEM cells in more 
detail. 
 
3.1 Generation of Recombinant MCMV: MCMV IE1/3flox 
The immediate-early genes ie1 and ie3 of MCMV were chosen to analyse the effect of 
persistent viral gene expression on the maintenance of MI. This was done because the 
mRNAs of ie1 and ie3 are detectable in latently infected organs several months after 
infection, hence in the absence of viral particles [72]. These genes encode peptides 
that induce MI in Balb/c and C57BL/6 mice [147, 148, 201]. To allow inducible deletion 
of ie1/3 ORFs, the genomic region was flanked with loxP sequences using a traceless 
mutagenesis method, described in detail in chapter 2.13.2 [160], [202]. 
The intermediate and final BAC constructs of MCMV IE1/3flox were confirmed by 
comparing their EcoRV restriction patterns to the MCMV WT BAC (Figure 12). The 
restriction pattern of the intermediate constructs carrying the galK/Kn cassette differed 
from the pattern of MCMV WT BAC in a manner that was consistent with in silico 
predictions. Constructs in which the galK/Kn cassettes were replaced by the loxP-sites, 
showed identical restriction patterns to MCMV WT BAC, because the loxP sequences 
are only 34 bp long and carry no restriction sites for EcoRV. The intermediate and final 
constructs were additionally validated by sequencing of the mutated sites. In all cases, 
no unwanted mutations could be identified. 
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To generate infectious virus, the MCMV IE1/3flox DNA was transfected into primary 
MEFs from C57BL/6 mice. The SN was harvested, passaged five times to remove the 
BAC sequence and then used to prepare virus stocks [26]. The stability of the loxP 
sequences in vitro was confirmed by PCR of virus stock DNA at loxP insertion sites, 
followed by sequencing of PCR products (data not shown). 
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Figure 12 EcoRV restriction pattern analysis of the intermediate and final constructs of 
MCMV IE1/3flox BAC. 
The restriction analysis was performed on a horizontal agarose gel and bands bigger than 
1,500 bp are displayed. Lanes were loaded with (M) the 1 kb DNA ladder, (1) the MCMV WT 
BAC, (2) the intermediate construct MCMV IE3 pA galK/Kn BAC, (3) the MCMV IE3 pA loxP 
BAC with one loxP site in the poly(A) tail, (4) the second intermediate construct MCMV IE3 pA 
loxP + IE1/3 Exon1 galK/Kn BAC and (5) the final MCMV IE1/3flox BAC. The red arrows indicate 
additional bands in comparison to the MCMV WT BAC restriction pattern. The green arrows 
indicate absent bands in comparison to the MCMV WT BAC restriction pattern. Please note that 
only the intermediate constructs, with large galK and Kn gene insertions show different 
restriction patterns, while the more discrete modifications carrying only the loxP sites show no 
differences relative to the MCMV WT. 
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3.2 MCMV IE1/3flox Replication In Vitro and In Vivo 
To ensure that the fitness of the recombinant MCMV IE1/3flox is similar to MCMV WT, 
the virus growth was examined by a multistep growth kinetic assay in vitro in NIH-3T3 
cells. The cells were infected in three independent experiments with MCMV IE1/3flox or 
MCMV WT at low MOI (0.1) and SNs were taken daily for 6 days and stored in -70°C 
until titration of infectious virus by plaque assay on MEFs could be performed. Results 
(Figure 13) argued that the recombinant virus replicated only slightly less well than the 
WT virus, but the final infectious titres were virtually identical. 
 
 
 
Figure 13 Insertion of loxP sequences into the ie1/3 locus does not influence viral growth 
of MCMV IE1/3flox in vitro. 
NIH-3T3 cells were infected in three independent experiments with MOI 0.1 of MCMV IE1/3flox 
or MCMV WT and SNs were harvested daily for 6 days and titrated on MEFs. Mean viral titres 
at indicated time points are shown. Vertical bars show the standard deviations (SD). 
 
Recombinant viruses with normal growth in vitro, may nevertheless present growth 
deficits in vivo [129, 203-205]. Thus the viral replication was also tested in mice. 
C57BL/6 mice were i.p. infected with 106 PFU/mouse MCMV IE1/3flox or MCMV WT. At 
five dpi, the spleen, liver and lungs were harvested in sterile conditions and stored at 
-70°C. Infectious virus titres were determined by p laque assay on MEFs. At dpi 21, 
infectious virus titres were determined in the salivary glands. As shown in Figure 14, 
the recombinant virus replicated comparably to the WT virus in all organs that have 
been tested. 
In summary, the insertion of the loxP sequences in the ie1/3 locus did not impair the 
viral growth in vitro or in vivo. 
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Figure 14 Insertion of loxP sequences into the ie1/3 locus does not influence viral growth 
of MCMV IE1/3flox in vivo. 
In vivo growth of MCMV IE1/3flox was compared to the growth of MCMV WT. C57BL/6 mice 
were i.p. infected with 106 PFU/mouse MCMV IE1/3flox or MCMV WT. The spleen, liver and 
lungs were harvested under sterile conditions at five dpi, and the infectious virus titres were 
determined by plaque assay on MEFs. The infectious virus titres in the salivary glands were 
determined at 21 dpi. Each symbol represents one mouse and the horizontal lines indicate the 
medians. 
 
3.3 Stability of Recombined MCMV IE1/3flox In Vivo 
The in vivo stability of the inserted loxP sequences was analysed by PCR of the ie1/3 
region after viral replication in vivo. C57BL/6 mice were i.p. infected with 
106 PFU/mouse MCMV IE1/3flox or MCMV WT and salivary glands were harvested 
21 days later. The organ was homogenised and layered on MEFs expressing the 
inducible Cre.ERT2 (generated from transgenic C57BL/6 R26Cre.ERT2 mice), which 
were preincubated for 48 h with 1 µM Tam to induce the Cre recombinase. The cells 
were incubated at 37°C for additional 48 h upon inf ection and the SNs were harvested 
and analysed by PCR with primers for the recombined ie1/3 gene locus (Figure 15). 
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Figure 15 Schematic representation of the PCR products before and after the 
recombination of the ie1/3 locus. 
The Primer binding sites flank the ORF of ie1/3, including the loxP sequences. In absence of 
recombination, the PCR results in a large PCR product (red arrow), whereas upon 
recombination, the PCR results in a small PCR product (grey arrow). 
 
The PCR product obtained from mice infected with MCMV IE1/3flox was smaller than 
the MCMV WT samples and had the predicted size of 283 bp (Figure 16). Therefore, 
the loxP sequences remained stable during several replication cycles of the virus in its 
host and could be efficiently recombined. 
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Figure 16 Function of the loxP sequences is stable after virus replication in vivo. 
MEFs expressing inducible Cre.ERT2 were cultured for 48 h in presence of 1 µM Tam, then 
infected with the salivary gland homogenates from C57BL/6 mice, which were i.p. infected with 
106 PFU/mouse MCMV IE1/3flox or MCMV WT for 21 days, and cultured for additional 48 h. SNs 
were harvested and used to analyse the ie1/3 gene locus for recombination by PCR with 
primers flanking the ORF of ie1/3. The PCR products were run on a horizontal agarose gel. The 
first lane shows the negative control, the second lane the 1kb DNA ladder and the third lane 
contains a PCR product with MCMV WT BAC as template. The 283 bp bands show PCR 
products consistent with Cre-mediated recombination of MCMV IE1/3flox. The experiment was 
done with samples from three different mice for each virus. 
 
3.4 MCMV IE1/3flox Fails to Reactivate from IFNβ-Induced Latency In Vitro 
The experimental strategy required that Cre recombinase targets a sufficient proportion 
of viral genomes to result in phenotypes that may be experimentally observed and 
quantified. Upon viral entry into the cell nucleus, cellular repressors and histones are 
recruited to the viral DNA (reviewed in [64]). It was shown that the MIEP is highly 
packaged in the latent phase of infection in vivo [74], and it was proposed that 
therefore transcription of immediate-early genes occurs only sporadically [47]. 
Therefore it was tested whether Cre recombinase may bind to and recombine a 
sufficient proportion of the introduced loxP sites to limit virus replication. Primary 
fibroblasts expressing constitutively active Cre recombinase under the strong CMV 
promoter were infected with MCMV. The growth and spread of the recombinant MCMV 
IE1/3flox was not impaired at all (Figure 17), suggesting that during the lytical virus 
cycle, the MCMV gene expression and replication may be too rapid for the Cre-
mediated targeting to recombine the loxP sites and thus inhibit MCMV replication and 
spread. Therefore, the efficient deployment of Cre recombinase required that viral 
genomes do not actively replicate, as it is the case during viral latency. 
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Figure 17 Cre recombinase does not influence viral growth of MCMV IE1/3flox in vitro. 
Cre-MEFs or Balb/c MEFs were infected in three independent experiments at MOI 0.1 of MCMV 
IE1/3flox and SNs were harvested every day for 6 days and titrated on C57BL/6 MEFs. Mean 
viral titres at indicated time points are shown. Vertical bars show the standard deviations (SD). 
 
Next, it was tested if the Cre recombinase may have a chance to recombine the latent 
genomes. A newly established in vitro latency model was used, where the addition of 
IFNβ reversibly inhibits immediate-early gene expression and MCMV replication in a 
manner consistent with viral latency (Dag et al, 2013, manuscript submitted). The 
addition of IFNβ one day before infection induces an anti-viral state in some, but not all, 
fibroblasts [206]. Hence, cells were infected with a very low MOI (0.0001), minimising 
the chance of infection of IFNß-unresponsive cells. The wells were scanned for 
cytopathic effects and MCMV IE1/3flox replication occurred in almost all IFNβ-untreated 
wells, similar to MCMV WT (Figure 18). In cells which constantly received IFNβ, viral 
replication was blocked efficiently throughout the experiment. Removal of IFNβ at 7 dpi 
restored the replication of MCMV WT in some wells, whereas MCMV IE1/3flox failed to 
reactivate in any well. These data indicated that Cre recombinase was able to act on 
the loxP sites and had sufficient time to excise the genes ie1 and ie3, in the presence 
of IFNβ-recruited cellular repressors of viral transcription and replication. 
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Figure 18 MCMV IE1/3flox failed to replicate upon IFNβ removal from Cre-MEFs. 
Cre-MEFs were treated with IFNβ and infected with MOI 0.0001 of MCMV WT (A) or MCMV 
IE1/3flox (B). Control cells were infected in the absence of IFNβ (-IFNβ, open circle). At 7 dpi, 
IFNβ was removed in selected wells (+/-IFNβ, grey circle) or resupplied at regular interval 
(+IFNβ, black circle). At the indicated time points after infection, the mean percentage is listed 
and the SEM is shown in vertical bars from five independent experiments. 
 
3.5 Immunological Phenotype of Recombinant MCMV IE1/3flox 
CD8+ T cells specific for a peptide derived from the protein IE3 are known to 
accumulate and remain maintained at high levels during latent infection of C57BL/6 
mice [147]. To test whether CD8+ T cells are primed correctly with the peptide derived 
from the IE3 protein of the recombinant virus, mice were infected with 106 PFU/mouse 
MCMV IE1/3flox or MCMV WT and the accumulation of IE3-specific CD8+ T cells was 
monitored over several months. Transgenic C57BL/6 mice, expressing the inducible 
Cre recombinase Cre.ERT2 under the control of the ubiquitous Rosa26 promoter, were 
i.p. infected and monitored at 0, 7, 14, 28, 60, 90 and 120 dpi, when blood samples 
were analysed for IE3-specific CD8+ T cells. The erythrocytes in the blood samples 
were lysed and the cells were incubated together with immunodominant peptides 
derived from the IE3, M45 or M38 gene. The cells were surface-stained with 
monoclonal antibodies against CD3, CD4, CD8a, CD44, and CD127 proteins and the 
response to the peptide stimulation was visualised by intracellular staining against IFNγ 
and TNFα (Table 1). 
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Table 1 Antibody panels used to analyse T cells from blood samples. 
Antibody Fluorochrom 
anti-CD3 allophycocyanin-eFluor780 
anti-CD4 Pacific Blue 
anti-CD8a PerCP-Cy5.5 
anti-CD44 AlexaFluor700 
anti-CD127 PE 
anti–IFNγ allophycocyanin 
anti–TNFα FITC 
 
After staining, cells were acquired with the LSRII cytometer and their populations were 
analysed by progressive gating with FlowJo software. The exemplary blots shown in 
Figure 19 illustrate that the cells were gated on single T lymphocytes, positive for CD8a 
and IFNγ. Furthermore the CD8+ T cells were separated for CD44 and CD127, to 
distinguish between TEM cells (CD44+, CD127-), TCM cells (CD44+, CD127+) and naive 
T cells (CD44-, CD127+). Fractions of populations were graphed and statistically 
analysed with Graphpad Prism software. 
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Figure 19 Gating strategy. 
The cells were first gated on the time of acquisition to exclude artefacts from acquisition bursts 
towards the end of acquisition. Cells within the time gate were analysed for forward and side 
scatter area (FCS-A and SSC-A) to gate on the lymphocyte population. Cell doublets were 
excluded from the lymphocyte gate by gating on cells, whose FCS-A linearly correlated to 
FCS-H. These cells were then separated for CD3 expression, to focus on T cells and then 
separated with CD4 and CD8a, to identify the CD8a+ T cells. The CD8+ T cells were analysed 
for IFNγ expression. 
 
To examine the response of the CD8+ T cells to the peptide stimulation, the time kinetic 
of the relative numbers of the IFNγ positive CD8+ T cells was measured (Figure 20). At 
7 dpi, the numbers of IFNγ+ CD8+ T cells were comparable in mice infected with MCMV 
IE1/3flox and those infected with MCMV WT. At 14 and 28 dpi the CD8+ T cells from 
mice infected with MCMV IE1/3flox showed a better response to the stimulation with 
IE3 peptide, but from 60 dpi on the responses were comparable again. The reason for 
the decreased response at the days 7 and 14 p.i. remained unclear, but it is unlikely a 
consequence of the experimental setup, because it happened before the Tam 
administration and the mice, infected with the recombinant virus did not show any 
deficit in IE3-specific CD8+ T cell responses. The negative control, consisting of mice 
injected with PBS (MOCK group), showed no expansion of cells responding to the 
peptide. 
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Figure 20 Kinetic of IE3-specific CD8+ T cells is comparable between mice infected with 
MCMV IE1/3flox and those infected with MCMV WT. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU of MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. Lymphocytes were stimulated with IE3 peptide 
and analysed by FCM. The groups reflect the IFNγ+ cells in the CD3+ CD4- CD8a+ population at 
0, 7, 14, 28, 60, 90 and 120 dpi. Pooled averages from 30 mice per group for infected mice and 
15 mice for the MOCK group are shown. The error bars indicate the SEM. 
 
To monitor the CD8+ T cell immune response to MCMV IE1/3flox in more detail, the 
kinetics of CD8+ T cells specific for another inflationary peptide, M38, and one 
non-inflationary peptide, M45, were monitored and compared between the same 
infectious groups (Figure 21). The kinetics for both specific CD8+ T cell responses 
showed no difference. 
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Figure 21 Kinetics of M45- and M38-specific CD8+ T cells are comparable between mice 
infected with MCMV IE1/3flox and those infected with MCMV WT. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. Lymphocytes were stimulated with M45 or M38 
peptide and analysed by FCM. The groups reflect the IFNγ+ cells out of the CD3+ CD4- CD8a+ 
population at 0, 7, 28 and 90 dpi for stimulation with M45 peptide (A) and 0, 14, 60 and 120 dpi 
for stimulation with M38 peptide (B). Pooled averages from 30 mice per group for infected mice 
and 15 mice for the MOCK group are shown. The error bars indicate the SEM. 
 
Taken together, the kinetics of CD8+ T cell responses indicated that the IE3 peptide is 
detected by CD8+ T cells upon MCMV IE1/3flox or MCMV WT infection, and that the 
responses to other viral peptides were also not impaired. Moreover, the results argued 
that non-activated Cre recombinase Cre.ERT2 does not abrogate the accumulation of 
the IE3-specific CD8+ T cells in the mice infected with the recombinant virus. 
 
3.6 Conditional Knock-Out of IE1/3 In Vivo 
The data argued that the recombinant virus MCMV IE1/3flox may be able to establish MI 
in the C57BL/6 R26Cre.ERT2 mice, because IE3-specific CD8+ T cells accumulated 
with the same frequencies as the MCMV WT control. We reasoned that the knock-out 
of the ie1/3 genes may be induced once the virus is latent by administering Tam to the 
mice. Tam administration was initiated at four months p.i. (120 dpi), because the 
infectious viral particles are not detectable anymore, but viral genomes are still present 
in the organs at this time [52], [207]. 
Latency also means that transcriptional repressors are bound to the MIEP and other 
viral promoters [74] to block viral gene expression. In the latent phase of infection the 
amount of deacetylated histons bound to the viral genome is greatly increased. 
Especially the MIEP is highly packed at >120 dpi [78]. However, random asynchronous 
transcription from the MIEP was observed during viral latency [71]. Therefore, it was 
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assumed that DNA may be exposed to the Cre recombinase during the transcriptional 
events that transiently relax the packaging of the viral genome. It followed that Tam 
would have to be administered for an extended time (4 weeks) to allow sufficient time 
for the Cre recombinase to bind to the loxP sites in the MIEP region once the DNA is 
not blocked by cellular repressors. To avoid prolonged stress to mice, Tam was 
administered in food pellets. It has been shown that the administration of pellets 
containing 360 mg/kg Tam for a period of 4 weeks was sufficient to ensure thorough 
recombination of chromosomally localised loxP target [184]. Pellets containing 
800 mg/kg or 400 mg/kg of Tam were tested for toxicity, and pellets with 800 mg/kg 
showed severe toxicity. On the other hand, no mortality was observed in uninfected 
female or male R26Cre.ERT2 mice upon administration of 400 mg/kg (data not shown). 
Hence, pellets containing 400 mg/kg of Tam were used in these experiments. 
 
15 mice infected with the MCMV IE1/3flox or MCMV WT were fed for 4 weeks with Tam 
pellets, while 15 control mice from each group were maintained on standard diet. 5 out 
of 30 mice fed with Tam died during the experiment. The mechanism of the toxicity and 
death has not been studied, and it remains unclear if it is related to direct Tam toxicity 
or caused by the activation of the Cre recombinase, but interestingly, all 5 mice which 
died were females. 
After four weeks of Tam administration, the mice were bled again and the lymphocytes 
were stimulated with the IE3 peptide. Mice fed with Tam showed a reduction of around 
40% of the IE3-specific CD8+ T cells (Figure 22). Surprisingly, this drop was not 
restricted to the group infected with MCMV IE1/3flox, because it was observed to the 
same extent in the group infected with MCMV WT. 
 
 
 
Results 
65 
 
 
 
Figure 22 Decreased percentage of IE3-specific CD8+ T cells in R26Cre.ERT2 mice 
infected with MCMV IE1/3flox and those infected with MCMV WT upon Tamoxifen 
administration. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. The lymphocytes were stimulated with IE3 
peptide and analysed by FCM for IFNγ production in cells out of the CD3+ CD4- CD8a+ 
population at 0, 7, 14, 28, 60, 90, 120 and 150 dpi. Mice were fed with Tam from 120 to 150 dpi 
(shaded rectangular area). Group averages from 15 mice per group are shown. The error bars 
indicate the SEM. 
 
To define whether the loss of cells affected only the MCMV-specific T cells, three major 
CD8+ T cell subsets were analysed, namely the naive T cells (CD8+ CD44- CD127+), 
the CD8+ TCM cells (CD8+ CD44+ CD127+) and the CD8+ TEM cells (CD8+ CD44+ 
CD127-). As shown in Figure 23, the percentage of TEM cells decreased in all mice 
exposed to Tam. On the other hand, the fraction of cells in the TCM compartment 
increased, whereas the percentage of naive T cells was not affected. 
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Figure 23 Decreased percentage of effector memory CD8+ T cells in R26Cre.ERT2 mice 
infected with MCMV IE1/3flox and those infected with MCMV WT upon Tamoxifen 
administration. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. Mice were fed with Tam from 120 to 150 dpi 
(shaded rectangular area). The lymphocytes were analysed by FCM. Shown are the kinetics of 
three subsets of the CD3+ CD4- CD8a+ population at 0, 7, 14, 28, 60, 90, 120 and 150 dpi. 
(A) The TEM cell compartment was defined as CD44+ and CD127-. (B) The TCM cell 
compartment was defined as CD44+ and CD127+. (C) The naive T cell compartment was 
defined as CD44- and CD127+. All panels show group averages from 15 mice per group. The 
error bars indicate the SEM. 
 
To define if the effect of Tam treatment on the CD8+ T cells is reversible, Tam treated 
mice were reverted to the standard diet and the T cells were monitored for two more 
months. As seen in Figure 24, the percentage of IE3-specific CD8+ T cells increased 
back to levels comparable to the groups which were not fed with Tam. Moreover, the 
relative numbers of TEM cells and TCM cells returned to the levels seen in the control 
groups (Figure 25). Therefore, the transient loss of virus-specific CD8+ T cells was not 
consistent with a permanent deletion of the ie1/3 gene from the virus genome. 
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Figure 24 Reversible decrease of IE3-specific CD8+ T cells upon Tamoxifen 
administration. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. Mice were fed with Tam from 120 to 150 dpi 
(shaded rectangular area). The lymphocytes were stimulated with IE3 peptide and analysed by 
FCM. Data reflect the percentage of IFNγ+ cells out of the CD3+ CD4- CD8a+ population at 0, 7, 
14, 28, 60, 90, 120, 150, 180 and 210 dpi. Averages from 15 mice per group are shown. The 
error bars indicate the SEM. 
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Figure 25 Reversible decrease of effector memory T cells upon Tamoxifen 
administration.  
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. Mice were fed with Tam from 120 to 150 dpi 
(shaded rectangular area). The lymphocytes were analysed by FCM. Data reflect the 
percentage of cells in the three subsets of the CD3+ CD4- CD8a+ population at 0, 7, 14, 28, 60, 
90, 120, 150, 180 and 210 dpi. (A) The TEM cell compartment was defined as CD44+ and 
CD127-. (B) The TCM cell compartment was defined as CD44+ and CD127+. (C) The naive T cell 
compartment was defined as CD44- and CD127+. All panels show averages from 15 mice per 
group. The error bars indicate the SEM. 
 
It remained unclear if the effects of Tam were due to its toxicity (direct, or mediated by 
an activated Cre.ERT2), or if they reflected a transient transcriptional suppression of 
MCMV genes, and consequently for induction of CD8+ T cells by the viral genome. 
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3.7 Influence of Tamoxifen on MCMV-Specific T Cells 
While the administration of Tam had a negative effect on the TEM cell compartment of 
MCMV-infected R26Cre.ERT2 mice, it remained unclear if Tam would have the same 
effect on T cells of mice that do not express the Cre.ERT2. 
C57BL/6 WT mice were infected with 106 PFU MCMV WT and fed with pellets 
containing 400 mg/kg Tam from 60 to 90 dpi, once the IE3-specific CD8+ T cells 
reached a level of more than 4% of the CD8+ T cell pool. The relative counts of 
different CD8+ T cell subsets were compared between the groups before the infection, 
to confirm that the increase in IE3-specific cells was due to virus infection, and before 
and after the Tam administration (at 60 and 90 dpi, respectively), to monitor the gain or 
the loss of virus-specific cells relative to the count prior to the administration. As shown 
in Figure 26, the percentage of IE3-specific CD8+ T cells did not decrease upon Tam 
treatment. In fact, consistent with data from R26Cre.ERT2 mice (Figure 20), the fraction 
of IE3-specific CD8+ T cells increased between days 60 and 90, and this gain was not 
slowed down by Tam administration. 
 
 
 
Figure 26 Administration of Tamoxifen to C57BL/6 mice, infected with MCMV WT, had no 
effect on the relative numbers of IE3-specific CD8+ T cells. 
Mice (C57BL/6) were i.p. infected with 106 PFU MCMV WT. The MOCK group was injected with 
200 µl PBS. Mice were fed with Tam from 60 to 90 dpi (shaded rectangular area). The 
lymphocytes were stained with an IE3-specific pMHC Dextramer and analysed by FCM. Data 
represent the Dextramer+ cells out of the CD3+ CD4- CD8a+ population at 0, 7, 60 and 90 dpi. 
Averages percentages from 15 mice per group are shown. The error bars indicate the SEM. 
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The CD8+ T cells were further analysed for the expression of the surface marker CD44 
and CD62L. In all three T cell compartments, TEM cells (CD8+ CD44+ CD62L-), TCM cells 
(CD8+ CD44+ CD62L+) and naive T cells (CD8+ CD44- CD62L+), there was no 
difference between the MCMV-infected groups fed with Tam pellets or with standard 
mouse chow (Figure 27). In the memory T cell subset a minor difference at 90 dpi 
could be observed, which did not reach to levels of statistical significance. 
 
A
B C
 
 
Figure 27 Kinetic of effector memory CD8+ T cells is not influenced by administration of 
Tamoxifen to C57BL/6 mice, infected with MCMV WT. 
Mice (C57BL/6) were i.p. infected with 106 PFU MCMV WT. The MOCK group was injected with 
200 µl PBS. Mice were fed with Tam from 60 to 90 dpi (shaded rectangular area). The 
lymphocytes were analysed by FCM. Data represent the fraction of indicated T cell subsets in 
the CD3+ CD4- CD8a+ population at 0, 7, 60 and 90 dpi. (A) The TEM cell compartment was 
defined as CD44+ and CD62L-. (B) The TCM cell compartment was defined as CD44+ and 
CD62L+. (C) The naive T cell compartment was defined as CD44- and CD62L+. All panels show 
percentage averages from 15 mice per group. The error bars indicate the SEM. 
 
To exclude the possibility that Tam has generalised toxic effects on the entire CD8+ 
T cell compartment, reducing the total CD8+ T cell count, while leaving the fraction of 
each subset intact, the absolute values have been investigated. At 90 dpi, the blood 
lymphocytes were stained with anti-CD8a, anti-CD44, anti-62L and anti-CD127 and 
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counted with an Accuri cytometer. The graphs in Figure 28 show the CD8+ T cell 
compartments phenotyped according to CD44 and CD62L expression. No significant 
difference between the infected groups could be seen. Again, in the TCM cell 
compartment there was a small difference between the group treated with Tam and the 
group without Tam, but the difference was not statistically significant. These data 
indicated that Tam does not influence the relative and absolute numbers of CD8+ 
T cells in MCMV-infected mice which do not express the Cre.ERT2. 
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Figure 28 Absolute numbers of effector memory CD8+ T cells are not influenced by 
administration of Tamoxifen to C57BL/6 mice, infected with MCMV WT. 
Mice (C57BL/6) were i.p. infected with 106 PFU MCMV WT. The MOCK group was injected with 
200 µl PBS. Mice were fed with Tam from 60 to 90 dpi. The lymphocytes were stained with anti-
CD8a, anti-CD44, anti-CD62L and anti-CD127 and analysed by FCM at 90 dpi. (A) The TEM cell 
compartment was defined as CD44+ and CD62L-. (B) The TCM cell compartment was defined as 
CD44+ and CD62L+. (C) The naive T cell compartment was defined as CD44- and CD62L+. All 
panels show percentage averages from up to 9 mice per group. The error bars indicate the 
SEM. 
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3.8 Effects of Tamoxifen Treatment in MCMV-Infected R26Cre.ERT2 Mice 
on Different Peptide-Specific CD8+ T Cells 
Tam transiently decreased the percentage of MCMV-specific T cells and the relative 
size of the TEM cell compartment in R26Cre.ERT2 mice, but not in the parental C57BL/6 
strain. 
 
In the previous chapters, the CD8+ T cells specific for the inflationary peptide IE3 were 
analysed, which predominantly exhibit a TEM phenotype. To define whether the loss of 
cells affected also the non-inflationary CD8+ T cells, the M45-specific T cells were 
analysed, which mostly have a TCM phenotype. As shown in Figure 29, the percentage 
of M45-specific CD8+ T cells was not affected upon the administration of Tam. 
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Figure 29 Administration of Tamoxifen to MCMV-infected R26Cre.ERT2 mice did not affect 
the percentage of M45-specific CD8+ T cells. 
Mice (C57BL/6 R26Cre.ERT2) were i.p. infected with 106 PFU MCMV IE1/3flox or MCMV WT. 
The MOCK group was injected with 200 µl PBS. The lymphocytes were stimulated with M45 
peptide and analysed by FCM for IFNγ production in cells out of the CD3+ CD4- CD8a+ 
population. Mice were fed with Tam from 120 to 150 dpi (shaded rectangular area). (A) IFNγ+ 
cells from 0, 7,  28, 90 and 150 dpi are shown. Group averages from up to 15 mice per group 
are shown. The error bars indicate the SEM. (B) IFNγ+ cells out of the CD3+ CD4- CD8a+ 
population from 150 dpi are shown. Each symbol represents one mouse and the horizontal lines 
indicate the medians. 
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For historical reasons, Rag2flox/floxxR26Cre.ERT2 mice were infected with a recombinant 
MCMV in an independent experiment. In this mouse strain, the Cre.ERT2 is expressed 
under the control of the Rosa26 promoter and both alleles of the rag2 are floxed. In 
theory, the somatic recombination would be prevented in the lymphocyte precursor 
cells of these mice upon Tam administration, and as a result naive T cells should not 
be generated anymore. Therefore, this study was initiated to investigate whether the 
recruitment of naive T cells to the IE3-specific T cells might have a significant influence 
on their accumulation. Due to the effects of Tam on the CD8+ T cell compartment in 
R26Cre.ERT2 mice (see chapter 3.6), the outcomes of this study could not be used to 
investigate the original question. However, this experiment was performed in a similar 
setup as the experiments shown in chapters 3.6 and 3.7, especially concerning the 
route of infection, the establishment of latent MCMV infection, as well as the Tam 
administration. Therefore, the results of this study were used to analyse whether the 
Tam induced effect was specific for the IE3-specific T cells within the TEM cell pool or if 
it might influence also other inflationary T cells in mice expressing Cre.ERT2. 
The virus, used in this experiment expresses the immunodominant peptide SSIEFARL 
in the IE2 locus (MCMV IE2SL). SSIEFARL is a peptide derived from the envelope 
protein gB of Herpes Simplex Virus 1 (HSV-1) and the recombinant virus has been 
recently described and analysed in our group [155]. The T cells specific for the 
SSIEFARL peptide inflate during latency and the majority of these cells belong to the 
TEM cell subset.  
 
The mice were infected with 106 PFU of the recombinant MCMV. The CD8+ T cells 
were monitored throughout the experiment and analysed by FCM. The mice were fed 
with pellets containing 400 mg/kg Tam from 60 to 90 dpi. After the administration of 
Tam, the relative counts of different CD8+ T cell subsets and peptide-stimulated T cells 
were analysed. As shown in Figure 30 the Tam administration led to a reversible drop 
of SSIEFARL and M38-specific T cells. 
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Figure 30 Administration of Tamoxifen leads to a reversible drop in the percentage of 
MCMV-specific CD8+ T cells. 
Mice (C57BL/6 Rag2flox/floxxR26Cre.ERT2) were infected i.p. with 106 PFU MCMV IE2SL. Mice 
were fed with Tam from 60 to 90 dpi (shaded rectangular area). The lymphocytes were 
stimulated with peptide and analysed by FCM. The groups reflect the IFNγ+ cells out of the 
CD3+ CD4- CD8a+ population at 0, 7, 14, 28, 60, 90, 120 and 150 dpi for stimulation with (A) 
SSIEFARL peptide or (B) M38 peptide. Averages from 15 mice per group are shown. The error 
bars indicate the SEM. 
 
The CD8+ T cells were also analysed for the percentage of effector memory (CD44+ 
CD127-), central memory (CD44+ CD127+) and naive (CD44- CD127+) T cells, to define 
if these T cell subsets would be influenced by Tam administration. The same results as 
in chapter 3.6 could be observed. The percentage of TEM cells dropped upon Tam 
treatment and the percentage of memory T cells increased at the same time, in a 
reversible manner. 150 dpi the percentages of effector memory and memory T cells 
were similar to those of untreated mice. 
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Figure 31 Reversible effect of activated Cre.ERT2 on effector memory CD8+ T cells. 
Mice (C57BL/6 Rag2flox/floxxR26Cre.ERT2) were infected i.p. with 106 PFU MCMV IE2SL. Mice 
were fed with Tam from 60 to 90 dpi (shaded rectangular area). The lymphocytes were 
analysed by FCM. Data reflect the percentages of cells in the three subsets of the CD3+ CD4- 
CD8a+ population at 0, 7, 14, 28, 60, 90, 120 and 150 dpi. (A) The TEM cell compartment was 
defined as CD44+ and CD127-. (B) The TCM cell compartment was defined as CD44+ and 
CD127+. (C) The naive T cell compartment was defined as CD44- and CD127+. All panels show 
averages from 15 mice per group. The error bars indicate the SEM. 
 
These data suggested that the Tam induced effect in R26Cre.ERT2 mice is not 
restricted to IE3-specific T cells but may influence all MCMV-specific inflationary T 
cells. 
Furthermore, this effect was reversible upon Tam retraction, but it remained somewhat 
unclear from which T cell compartment the TEM cell pool was refilled. Theoretically, in 
MCMV-infected Rag2flox/floxxR26Cre.ERT2 mice, the percentage of TEM cells should not 
come back upon Tam administration as it occurred in this study, if the recruitment of 
newly generated naive T cells to that pool plays an important role. Therefore, although 
the absolute count of naive T cells was not verified upon Tam treatment to analyse the 
successful recombination of the Rag2 gene, these results would corroborate the 
previously published data that recent thymic emigrants are not required for the 
maintenance of TEM cells in a MCMV infection [158]. 
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3.9 Toxic Effect of Activated Cre.ERT2 on the Effector Memory T Cell 
Subset 
Activated Cre.ERT2 has a toxic effect on immature cells of the hematopoietic cell 
lineage [208]. It was described that the conditional Cre recombinase has access to the 
temporally unpacked genome in highly proliferating cells and is able to induce 
chromosomal abnormalities in them [208]. In this line, Thyagarajan et al., could show 
that the mammalian genome contains active recombinase recognition sites, the so-
called pseudo-lox sites, which support Cre-mediated chromosomal integration and 
excision [209]. 
A possible explanation for the decrease in the relative counts of TEM cells was that 
these cells still proliferated and thus suffered from Cre-induced chromosomal 
abnormalities. To investigate this scenario, the different T cell subsets were analysed 
for apoptosis upon Tam treatment of latently infected R26Cre.ERT2 mice. 
C57BL/6 R26Cre.ERT2 mice infected for 21 month with 106 PFU/mouse MCMV WT 
were fed with pellets containing 400 mg/kg Tam for 2 weeks. Upon Tam treatment, the 
splenic lymphocytes were harvested and stained with Annexin V antibodies and 7AAD. 
A conjugate of Annexin V and a fluorescent label can be used to detect apoptotic cells, 
as Annexin V binds to phosphatidylserine which is exposed on the cell surface only 
during apoptosis. 7AAD is a fluorescent chemical, intercalating into double-stranded 
DNA, but unable to pass the intact cell membrane. Therefore it is used to detect 
apoptotic or necrotic cells, in which the cell membrane is already permeable. Using 
these compounds in combination allows dividing the apoptotic cells into early-apoptotic 
(Annexin V+ 7AAD-) and late-apoptotic/necrotic ones (Annexin V+ 7AAD+ or 7AAD+ 
only) [210], [211]. The cells were stained for CD8, CD44 and CD62L expression and 
analysed for cell death type in the three CD8+ T cell subsets identified by CD44 and 
CD62L expression. Upon splenocyte isolation, the cells were counted. The spleens of 
mice fed with Tam had fewer cells than the control group, which was not unexpected, 
as a Tam induced loss of cells in the spleen of R26Cre.ERT2 mice has already been 
described [208]. The percentages of the three CD8+ T cell subsets were not 
significantly altered, although a minor reduction could be seen in the effector memory 
subset of Tam fed mice (Figure 32). 
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Figure 32 Effector memory T cells are not decreased after 2 weeks of Tamoxifen 
administration in R26Cre.ERT2, infected with MCMV WT. 
C57BL/6 R26Cre.ERT2 mice were i.p. infected with 106 PFU MCMV WT. 21 months later, mice 
were fed with pellets containing 400 mg/kg Tam for 2 weeks. 4x106 splenocytes were stained for 
CD8a, CD44 and CD62L expression. Pooled averages from 4 mice per group are shown. Error 
bars indicate SEM. Significance was assessed by Mann-Whitney U test (two-tailed) *p < 0.05. 
 
The different T cell subsets were analysed with Annexin V and 7AAD for cell death. As 
can be seen in Figure 33, only the TEM cells showed elevated percentages of late-
apoptotic/necrotic cells. The fraction of apoptotic cells remained the same upon Tam 
treatment in the central memory and naive T cell compartment. Since the death rate of 
TCM and naive T cells was not affected by Tam administration, the data argued that the 
reduction of the TEM cell compartment (Figure 25 and Figure 31) was not caused by the 
loss of naive or TCM cells replenishing the effector memory pool. In contrast, TEM cells in 
the spleen were directly targeted upon Tam administration to the R26Cre.ERT2 mice, 
strengthening the evidence that elevated fractions of the inflationary CD8+ T cells and 
the effector memory subset are maintained (at least in part) by cycling TEM cells. 
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Figure 33 Activated Cre.ERT2 induce cell death only in the effector memory CD8+ T cells. 
C57BL/6 R26Cre.ERT2 mice were i.p. infected with 106 PFU MCMV. 21 months later, mice were 
fed with pellets containing 400 mg/kg Tam for 2 weeks. 4x106 splenocytes were stained for 
CD8a, CD44, CD62L, 7AAD and Annexin V. (A) CD8+ TEM cells (CD8+ CD44+ CD62L-) were 
analysed with 7AAD and Annexin V. (B) CD8+ TCM cells (CD8+ CD44+ CD62L+) were analysed 
with 7AAD and Annexin V. (C) The naive T cells (CD8+ CD44- CD62L+) were analysed with 
7AAD and Annexin V. Pooled averages from 4 mice per group are shown. Error bars indicate 
SEM. Significance was assessed by Mann-Whitney U test (two-tailed) *p < 0.05. 
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4 Discussion 
In HCMV seropositive individuals ~10% of the CD4+ and CD8+ T cells were found to be 
HCMV-specific [152]. The same phenomenon was observed also in mice where 
CMV-specific CD8+ T cells with a TEM phenotype inflate through the lifetime of latently 
infected hosts. This progressive accumulation of specific cytotoxic CD8+ TEM cells is 
termed memory inflation (MI) [148]. We showed recently that the absolute number of 
CD8+ T cells is increased in MCMV-infected mice, but also that their composition is 
permanently altered, where the defining phenotype is a drastic increase of the 
proportion of TEM cells [153]. 
To understand the dynamic of MI, two questions need to be addressed: From which 
T cell pool do the inflationary TEM cells come and why do they accumulate over time? 
 
Recent thymic emigrants in the naive T cell compartment are not likely contributors to 
MI, because the CMV specific CD8+ T cells accumulate also in thymectomised mice 
[136]. Since CMV-specific TEM cells have been described as short-lived cells, which do 
not proliferate extensively upon adoptive transfer, the TCM cells have been suggested 
as a possible source of cells which replenish the TEM cell pool [150]. MI also occurs and 
is maintained in mice whose APCs are unable to cross-present antigens to T cells in 
the latent phase of infection [93], but also in mice infected with a recombinant MCMV 
that is unable to reactivate [157]. It has therefore been proposed that local viral gene 
expression during latency might stimulate TCM cells in the lymph nodes, resulting in 
their proliferation and differentiation into TEM cells [159]. 
 
This work has aimed to study the effect of persistent viral gene expression on the 
maintenance of MI by means of a recombinant MCMV, allowing the conditional deletion 
of an essential and immunodominant genomic region. 
The immediate-early genes ie1/3 of MCMV were targeted for conditional deletion, 
because they are transcribed at low levels during viral latency and IE1- or IE3-specific 
TEM cells accumulate over time of infection [147, 148]. Therefore, the ie1/3 exons 1 to 5 
were flanked by two loxP sites and transgenic mice expressing a Tam inducible Cre 
recombinase (Cre.ERT2) were infected with the recombinant MCMV IE1/3flox. Hence, 
the administration of Tam, allowed the selective targeting of the loxP sites at times of 
viral latency. 
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It was considered that the Cre recombinase may not easily reach its target and perform 
the recombination once the latent viral genome is highly associated with cellular 
repressors and deacetylated histones [74, 78]. While this condition prevents the 
RNA-Polymerase from binding to viral promoters, resulting in a transcriptionally inactive 
viral genome, the same chromatinisation may have also presented an obstacle for the 
binding of the Cre recombinase to the loxP sites and thus recombination. However, the 
presence of ie1 and ie3 transcripts during viral latency indicates that the ie1/3 locus is 
not permanently silenced [53]. Studies from the Koszinowski group showed that the 
Cre recombinase can bind loxP sites in the viral genome and recombines up to 90% of 
viral genomes in vivo [169, 212]. The in vitro data from this study indicated that the Cre 
recombinase cannot prevent MCMV IE1/3flox replication, but that it may be able to 
recombine viral genomes that are silenced by IFNβ. It is important to note that MCMV 
IE1/3flox grew comparably to the WT virus in cells expressing Cre recombinase in vitro, 
probably indicating that the ie gene expression and viral DNA replication is much 
quicker than Cre-mediated recombination in most of the infected cells. On the other 
hand, when the MCMV IE1/3flox or the MCMV WT replication and spread were inhibited 
by IFNβ, Cre had significantly more time to act on the viral genomes and IFNβ 
retraction at 7 dpi reactivated MCMV WT in 20% of the infected wells, whereas MCMV 
IE1/3flox failed to reactivate (Figure 18). In sum, these results were consistent with a 
scenario where the Cre recombinase recombined the silenced ie1/3 locus, resulting in 
an IE3 deficient MCMV, which could not grow any longer. 
 
The selective pressure from the host immune system might cause mutations in the 
MCMV genome which are favourable for virus replication. This may also affect the 
exogenously inserted loxP sites. Therefore, it was important to check the modified 
region upon several replication cycles of the recombinant MCMV in vivo. For this, viral 
DNA was isolated from the mouse 3 weeks after infection to sequence the loxP sites 
and no mutations were found. In addition, the functionality of the loxP sites of the virus 
isolated from mice was analysed in vitro and no impairment was found (chapter 3.3). 
These data suggested that the loxP sequences are not affected during viral replication 
in vivo and that they would keep their functionality in the latent phase of infection, once 
the Cre recombinase would be induced to target them. 
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This study focused on the accumulation of CMV-specific CD8+ T cells and in particular 
on the IE3-specific CD8+ T cells recognising the immunodominant and inflationary 
peptide RALEYKNL (reviewed in [137] and [147]). The CD8+ T cells of MCMV IE1/3flox-
infected R26Cre.ERT2 mice showed comparable accumulation from 60 dpi to those of 
mice infected with the MCMV WT (Figure 20). These data indicated that the insertion of 
the loxP sequences into the ie1/3 locus and the presence of inactive Cre.ERT2 had not 
impaired the establishment of MI. 
 
Tam was administered over a period of four weeks to R26Cre.ERT2 mice, starting at 
120 dpi, once MCMV latency has already been established [52, 207]. This resulted in a 
shift in the T cell subsets within the CD8+ T cells of MCMV IE1/3flox-infected mice, but 
unexpectedly also of control mice infected with MCMV WT: The percentage of TEM cells 
was decreased, the proportion of the TCM cell subset was increased, whereas the 
percentage of naive T cells was not affected (Figure 23). The same phenomenon could 
be observed within the IE3-specific CD8+ T cells, where the percentage decreased 
from 5 to 3 percent (Figure 22). The CMV-specific CD8+ T cells with an inflationary 
phenotype are part of the TEM cell subset. Since no decrease was noted in the TCM and 
naive T cell subsets, it seemed as though only the CMV-specific T cells have been 
affected. 
Tam is widely used in breast cancer therapy, where it blocks the oestrogen-receptor 
and thus decrease the risk of oestrogen-induced breast cancer return (reviewed in 
[213]). However, it can have severe side effects. Patients treated with Tam may have 
an increased risk of venous thrombosis, pulmonary emboli or uterine cancer [214, 215] 
and to develop non-alcoholic steatohepatitis [216]. In experiments with rats, even a 
carcinogenic effect on the liver could be observed [217]. It has also been shown that 
Tam inhibits MHC-II expression in DCs and therefore could have an influence on the 
stimulation of CD4+ T cells [218], which in turn could have an influence on the MI of 
IE3-specific T cells [46]. However, this effect appeared entirely dependent on the 
presence of Tam together with Cre.ERT2, because it did not occur in the absence of 
Tam or in mice lacking Cre.ERT2. Experiments with another R26Cre.ERT2 positive 
mouse line and another recombinant MCMV presented the same Tam-induced effect 
on the frequency of TEM cells (Figure 30 and Figure 31), but Tam had no effect on the 
numbers of IE3-specific T cells and TEM cells in C57BL/6 mice infected with MCMV WT 
(Figure 26 - Figure 28). 
Therefore, Tam appeared not to cause the decline of IE3-specific or TEM CD8+ T cells 
in the absence of Cre.ERT2. 
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The Cre recombinase specifically recognises the loxP sites and recombines the DNA 
sequence next to it upon moderate expression such as under the control of the Rosa26 
promoter. However, when it is expressed from a highly active promoter, the enzyme 
may bind to genomic sequences which resemble loxP sites and thus rise to 
chromosomal rearrangements [219]. The highly activated Tam-inducible variants are 
also assumed to act on the genomic DNA. It is assumed that the enzyme does not bind 
randomly in the genome, but rather at specific sites with conserved motifs. It is known 
that Cre can tolerate some mutations in the loxP sequence, and sequences that are 
almost identical in their sequence to the loxP sites have been found in the mammalian 
genome and termed pseudo or cryptic loxP-sites [220]. For some of these sites 
Cre-mediated recombination has already been proven [209]. As well as for the normal 
Cre recombinase, chromosomal abnormalities were detected for the Tam-inducible 
Cre.ERT1/2 in vitro in MEFs and in vivo in bone marrow-derived cells [208, 221]. 
Higashi et al. described toxic effects of the highly activated Cre.ERT2 on embryonic 
tissue and hematopoietic cells [208]. In embryos, the activation of Cre.ERT2 resulted in 
haematological changes and lower liver and body weight. To analyse effects in the 
adult mice, their group focused on the bone marrow, the thymus and the spleen and 
described a decrease in cell number after Tam treatment in these organs. This effect 
was especially pronounced in the immature cells of the haematopoietic cell lineage, like 
erythroblasts or immature B cells and the CD4 CD8 double-positive T cells in the 
thymus. Likewise, the number of myeloid cells was decreased in the bone marrow and 
spleen, whereas the differentiation of bone marrow-derived progenitor cells into 
myeloid cells and their survival did not seem to be affected in vitro. Importantly, the 
number of proliferating cells was reduced in the thymus and the number of apoptotic 
cells was increased in the spleen, but the mature B cells and the cell density in the 
white pulp of the spleen were not affected. They concluded that activated Cre.ERT2 
affects proliferating cells and increase apoptosis in immature cells of the hematopoietic 
cell lineage in primary lymphoid tissues as well as in the spleen. 
This might imply that either immature haematopoietic cells or the highly proliferating 
ones (or cells that satisfy both criteria) are more sensitive to Cre-mediated toxicity. The 
reasons for that specific toxicity are unknown, but it might be due to cell type-specific 
gene expression and the associated epigenetic modifications. 
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The data from this work showed a decrease in TEM cells that occurred only upon Tam 
application in mice expressing the Cre.ERT2. The inactivated Cre.ERT2 did not affect the 
composition of the T cell subsets and the Tam alone resulted in no changes as well. 
This indicates that the Tam-activated Cre recombinase acted on mature CD8+ T cells, 
which has not been described to date. The effect was reversible, as one month after 
completion of Tam treatment the percentages of T cell subsets recovered to levels 
seen in untreated mice. 
 
Taking these results together, the conditional Cre recombinase expressed under a 
ubiquitous promoter cannot be used to analyse effects on MCMV-specific CD8+ T cells. 
Although, the initial question could not be answered due to the limitations of the 
experimental model, the very same feature of the experimental system allowed the 
study of the origin of the CMV-specific CD8+ T cells with inflationary phenotype during 
latency. 
 
In theory, the T cell pool of MI could be maintained by long-term survival of cells in this 
compartment or by replenishing by the recruitment of naive T cells, the proliferation of 
TEM cells and the proliferation and differentiation of TCM cells. Naive T cells may be 
recruited to the MI pool, but their presence is not necessary to maintain the inflationary 
T cells [150, 158]. Snyder et al. showed that memory-inflated cells in the MCMV-
specific TEM cell subset are short-lived [150]. These cells have a half-life of ~ 45 - 60 
days, so the MI pool would have to be constantly replenished by newly differentiated 
TEM cells. Torti et al. demonstrated that the CD8+ T cells specific for the inflationary 
epitope M38 are mainly composed of TCM cells and to a lesser extent of TEM cells in the 
lymph nodes and hypothesised that latently infected non-hematopoietic cells stimulate 
MCMV-specific TCM cells in lymph nodes to proliferate and differentiate into TEM cells, 
which migrate into the peripheral tissues and do not further proliferate [159]. They did 
not experimentally prove that latent MCMV is present in the LN, and they did not 
address the possibility that other organs (e.g. spleen) may be relevant for the 
maintenance of the pool of MCMV specific CD8+ T cells. Others demonstrated that the 
spleen is a site of CMV latency [50, 52] and that splenic TEM cells may proliferate in a 
latently infected mouse, although not as good as TCM cells [150]. Hence, it is possible 
that both memory subsets may be involved in the production of MCMV-specific 
TEM cells that migrate to the end organ [159]. On the other hand, little to no proliferation 
of MCMV-specific CD8+ T cells takes place in the lung [159, 222], although this is a 
major site of virus recurrence [223], while T cell proliferation takes place in the lymph 
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nodes of the very same mice [159]. Taken together, the data indicate that the ability of 
inflationary T cells to proliferate may critically depend on the organ in which they 
reside, either due to the presence of antigen-presenting cells or the cytokine profile of 
the organ or both. 
 
All three T cell subsets, naive T cells, TCM and TEM cells are found in the spleen 
(reviewed in [187, 188]). Therefore, it was feasible that the toxic effect of the activated 
Cre.ERT2 on metabolically active cells or the proliferating T cell subset may be 
identified in this organ. 
Different splenic CD8+ T cell subsets of latently infected R26Cre.ERT2 mice infected 
with MCMV WT for 21 month were analysed for apoptosis upon 2 weeks of Tam 
administration. Total splenocyte counts were lower than in the control group, in line 
with data from published literature [208]. The only T cell subset with significantly 
increased apoptosis after Tam treatment, were the TEM cells. This implies that the 
CD8+ T cells with an effector memory phenotype (CD44+ CD62L-) were the major target 
for the highly activated Cre.ERT2 in the spleen. In contrast the TCM cells (CD44+ 
CD62L+) and the naive T cells (CD44- CD62L+) were not affected by the toxic effect of 
Cre.ERT2. These result differs from the results that one would expect from the model 
proposed by Snyder et al. and Torti et al., where such a decrease would rather have 
been expected in the pool of TCM cells, as they appeared to have the largest ability to 
proliferate and to differentiate [150, 159]. 
The induction of apoptosis could be a response to either chromosomal abnormalities 
during the proliferation of the TEM cells or during the differentiation from TCM cells to TEM 
cells. Moreover, the presence of T cell survival signals might play a role. The cytokines 
IL-7 and IL-15 are known to be involved in generating and maintenance of TCM cells 
(reviewed in [224]). In the spleen, as well as in the lymph nodes, IL-7 is produced by 
splenic stromal cells, which are located in the T cell rich white pulp [225]. IL-15 is 
produced for example by professional APCs [226, 227]. Additionally, the cytokines IL-2, 
secreted by lymphocytes, and IL-12, secreted by APCs, are involved in T cell 
proliferation [228]. However, the survival of TEM cells is not dependent on IL-7 and IL-15 
as they have low or no expression of the IL-7 receptor CD127 or the IL-15 receptor 
CD122 [149]. Since the relative number of naive T cells and TCM cells was not affected 
upon Tam administration in R26Cre.ERT2 mice and these cells did not show increased 
apoptosis, it is unlikely that the effects of Tam administration were due to effects 
involving IL-7 or IL-15 expression levels in the spleen. Potential indirect Cre toxicity on 
TEM cells by a suppression of IL-2 or IL-12 cannot be formally excluded, as the level of 
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cytokines was not examined in the samples. IL-12 is, among others, secreted by cells 
of the myeloid cell lineage, especially by professional APCs [228]. It was shown that 
the absolute number of cells positive for the markers CD11b and Ly6G (myeloid cells) 
are decreased after R26Cre.ERT2 mice received Tam [208]. Whether these cells were 
dead or migrated out of the spleen had not been studied, but the differentiation and 
maintenance of CD11b cells in vitro was not impaired in the presence of Tam [208]. 
The lack of data about the cytokine profile of the spleen before and after the Tam 
administration in R26Cre.ERT2 mice allows the possibility that differences in IL-12 
secretion affected the death rate of TEM cells, although this would imply that IL-12 is 
necessary only for the survival of TEM and not TCM cells. In conclusion, the role of IL-12 
in the Cre-mediated killing of TEM cells may be addressed in future studies by 
addressing the in vivo proliferation of the various T cell subsets. 
TEM and TCM cells differ in the expression of various surface molecules, but also in their 
functions and gene expression profiles. This difference could possibly lead to 
differences in genomic regions that would be accessible to the Cre recombinase in 
these cell types. Therefore, it is not possible to formally exclude the possibility that 
highly activated Cre recombinase may have access to pseudo loxP sites exclusively in 
TEM cells. The same could have happened during the differentiation of a TCM cell to a 
daughter TEM cell. On the other hand, it is also possible that TEM cells in the spleen are 
capable of proliferation that is comparable to or better than the TCM cells and therefore 
would be more susceptible to Cre-mediated toxicity. 
 
The initial question of this work could not be answered because the selected model 
system of Tam-induced Cre recombinase turned out to be unsuitable to study MI of 
CD8+ T cells in an MCMV infection. However, there are other experimental mouse 
models that could be tested to study the influence of ie1/3 expression on MI with the 
Cre/loxP system. 
 
In one system, the expression of Cre recombinase can be controlled by the 
administration of Tetracycline or its derivate Doxycycline (Dox). In this model, the Cre 
recombinase is expressed under the control of a weak promoter. Between the 
enhancer and the promoter are binding sites (operator sequences or tetracycline-
responsive elements (tetO)) for the reverse tetracycline-controlled transactivator (rtTA) 
which is also encoded in the mouse genome. The rtTA binds to the tetO elements only 
upon Dox administration and thereby activates the transcription of the Cre 
recombinase. (reviewed in [229]) 
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However, this system has limitations, because even in the absence of Dox there is a 
basal expression of Cre recombinase.  
 
Furthermore it may be possible to use mouse models with constitutive expression of 
active Cre recombinase. The CMV-Cre transgenic mice express the Cre recombinase 
ubiquitously under the control of the strong HCMV minimal promoter [230]. Here, the 
ie1/3 region would be targeted by the Cre recombinase in all cells during the primary 
infection and viral latency, increasing the chance of recombination. However, this is 
also the disadvantage of this mouse line. The knock-out of the ie1/3 region would be 
initiated immediately upon infection in all infected cells, which may diminish the latent 
load of the virus, in contrast to the system where the knock-out could be induced at a 
defined time point, once the virus is already latent. 
Other interesting transgenic mouse lines are the mice which express the Cre 
recombinase in endothelial cells (ECs) only, under the control of the EC-specific Tie-2 
promoter [231-233]. The Tie-2 promoter is active in all ECs during the embryogenesis, 
but also in the adult animal [231, 234]. These mouse lines would be particularly 
interesting, since ECs are proposed to be a site of latency for MCMV, which has 
already been proven for the LSECs [53]. This system also relies on the 
Cre recombinase that is constitutively active during primary infection, but the ECs play 
only a minor role in the reproduction and spread of MCMV in the primary phase of 
infection [235]. Using these mice it could be clarified, whether ECs are the only cell 
type in which the virus remains latent and further if the ie1/3 gene expression in these 
cells is necessary for the induction or maintenance of MI. 
 
The study of the interaction of CMV and its host remains an arduous task, since 
infection with CMV can affect every organ in the body, in both the acute and latent 
phase. In the organs and tissues all three CD8+ T cell subsets have been identified, but 
their composition may vary. In the lungs high amounts of TEM cells have been detected 
[236], whereas in the lymph nodes more naive T cells have been located [153], which 
is due to the cell composition and the cytokine profile within the organ. Published data 
indicated that the MCMV specific TCM cells have high proliferative capacity in the lymph 
nodes [159], and thus should be affected by the Cre-mediated toxicity in R26Cre.ERT2 
mice. Instead we observed significant cell death within the TEM cell population, but no 
increase in apoptosis in TCM and naive T cells upon Tam treatment in the spleen. 
Therefore, for a more conclusive statement about the proliferative capabilities of the 
different CD8+ T cell subsets in the spleen, the cells would need to be directly tested for 
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their in vivo proliferation, for instance by assessing the expression of Ki-67 (reviewed in 
[237]), or other markers of cell cycling in the different subsets. 
 
In conclusion, despite the limitations of the Tam-inducible Cre/loxP system that leads to 
the Cre-mediated toxicity on the CD8+ T cells, the data from this work argue that 
MCMV infection of R26Cre.ERT2 mice presents a novel model to study the proliferative 
capacity of memory CD8+ T cell subsets. Therefore, this system offers great potential 
as a tool to characterise the drivers and the mechanisms of the maintenance of the 
memory CD8+ T cell compartment under homeostatic conditions. 
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6 Appendix 
 
6.1 Primer and Construct List 
 
Table 2 List of Primers used in this study.  
The Primers were designed with the software Vector NTI and ordered at Eurofins MWG Operon 
(Ebersfeld, DE). 
denotation sequence size gene/ 
plasmid 
1 ATCATCCGTTGCATCTCGTTG 21-mer MCMV m54 
9 GTGTACTAGTGCTCTTCTTAGTTATGTATC
TACATATTTTACAAAACAGGGTTCATCTTT
AATACCACCTGTTGACAATTAATCATCGG
CA 
91-mer pGPS/galKn 
11 GTGTAAGCTTGCTCTTCCATCATGAGGAT
GAGTCTGGGGAGTATGAGTCTGACTGCG
AGTGATCTGTGCCAGTGTTACAACCAATT
AACC 
90-mer pGPS/galKn 
18 GGATTTATTTAATAGGGTTCGACATGAG 28-mer MCMV ie1/3 
19 TGAATCCTCTTCCCATCTATGAG 23-mer MCMV ie1/3 
20 GCCTGCATTACCGGTCGATGCAACGA 26-mer Cre.ERT2 
21 GTGGCAGATGGCGCGGCAACACCATT 26-mer Cre.ERT2 
43 GCTCTTCACCGAGCGGGTCCGATGCGCT
TCAGTAGCCGGGGAAGGTCGCTCTTTCTT
CCTGTTGACAATTAATCATCGGCA 
81-mer pGPS/galKn 
45 GCTCTTCGTCGCAGTCTTCGGTCTGACCA
CCGTAGAACGCAGAGCTCCTCGCTGCAG
GCCAGTGTTACAACCAATTAACC 
80-mer pGPS/galKn 
46 ACCAATATGGCGGCTGTTCC 20-mer MCMV ie1/3 
47 TGGCACGCATTCTATTGGCT 20-mer MCMV ie1/3 
97 CGCCAGTCTGTATCCGTCCAT 21-mer MCMV m54 
102 CAGCGCTCCTCCTGATAC 18-mer Rag2flox 
103 TGCATTCCTAGAGCGTCCTT 20-mer Rag2flox 
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135 CTGTGGACAGAGGAGCCATAACTGC 25-mer Rosa26 
136 CCACCACTGGCTGGCTAAACTCT 23-mer Rosa26 
300 ACGACCAAGTGACAGCAATG 20-mer Cre 
301 CTCGACCAGTTTAGTTACCC 20-mer Cre 
351 GCCAGCTGAGACTTGGCATCCAGGAAAG
GC 
30-mer MCMV ie1/3 
352 ATGAGCTACGTAGGTGAGGCCATAGTGG
CA 
30-mer MCMV ie1/3 
353 ATCAATCAGCCATCAACTCTGCTACCAAC
A 
30-mer MCMV ie1/3 
354 ATGGTGAAGCTATCAAAGATGTGCATCTC
A 
30-mer MCMV ie1/3 
 
Table 3 List of construct used in this study. 
The constructs contain the loxP sequence and homology sequences to the site in the viral 
genome at which the loxP sequence was introduced. They were designed with the software 
Vector NTI and ordered at the listed company. 
construct sequence company 
loxP sequence at 
the 3’ end of ie3 
TTAATTAAAAGCTTAGTTAGTTAGTTAGT
TATGTATCTACATATTTTACAAAACAGGG
TTCATCTTTAATACCAATAACTTCGTATA
ATGTATGCTATACGAAGTTATACAGATCA
CTCGCAGTCAGACTCATACTCCCCAGAC
TCATCCTCATGATGGCTTATATCAAAGCT
TGGCGCGCC 
GENEART 
(Regensburg, DE) 
loxP sequence into 
Exon 1 of ie1/3 
TCCCAATAGAACCGAGCGGGTCCGATG
CGCTTCAGTAGCCGGGGAAGGTCGCTC
TTTCTTATAACTTCGTATAATGTATGCTA
TACGAAGTTATCTGCAGCGAGGAGCTCT
GCGTTCTACGGTGGTCAGACCGAAGAC
TGCGACGGTACCGACG 
Eurofins MWG 
Operon (Ebersfeld, 
DE) 
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6.2 PCR Mix and Programs for Viral Mutagenesis 
 
6.2.1 MCMV ie3 pA galK-Kn 
 
To amplify the galKn cassette from the pGPS/galKn plasmid with primers having 
homologies to the 3’ end of ie1/3 the following mix was used: 
 
50 µl in total: 
 
1 µl 
10 µl 
1 µl 
1 µl 
1 µl 
5 U 
Adjust to 50 µl 
4 ng Plasmid-DNA 
5x Puffer 
dNTPs (2,5 mM each dNTP) 
Primer 9 (10 pmol) 
Primer 11 (10 pmol) 
LongAmp DNA Polymerase (NEB, MA, USA) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  64°C for 30 sec 
5. Elongation  72°C for 2 min 
6. Repeat   step 3. to 5. 18 times with reduction of annealing  
     temperature for 1°C every cycle 
7. Denaturing  94°C for 30 sec 
8. Annealing  45°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. – 9. 17 times 
11. Elongation  72°C for 7 min 
12. Storage  at 4°C 
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6.2.2 MCMV ie3 pA loxP 
 
To amplify the ie3 pA loxP construct from the plasmid send by GENEART the following 
mix was used: 
 
50 µl in total: 
 
1 µl 
10 µl 
1 µl 
1 µl 
1 µl 
5 U 
Adjust to 50 µl 
4 ng Plasmid-DNA 
5x Puffer 
dNTPs (2,5 mM each dNTP) 
Primer 18 (10 pmol) 
Primer 19 (10 pmol) 
LongAmp DNA Polymerase (NEB, MA, USA) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  60°C for 30 sec 
5. Elongation  72°C for 1 min 
6. Repeat   step 3. to 5. 18 times with reduction of annealing  
     temperature for 1°C every cycle 
7. Denaturing  94°C for 30 sec 
8. Annealing  45°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. – 9. 25 times 
11. Elongation  72°C for 7 min 
12. Storage  at 4°C 
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6.2.3 MCMV ie1/3 Exon1 galK-Kn 
 
To amplify the galKn cassette from the pGPS/galKn plasmid with primers having 
homologies to the 5’ end of ie1/3 the following mix was used: 
 
50 µl in total: 
 
1 µl 
10 µl 
1 µl 
1 µl 
1 µl 
5 U 
Adjust to 50 µl 
4 ng Plasmid-DNA 
5x Puffer 
dNTPs (2,5 mM each dNTP) 
Primer 43 (10 pmol) 
Primer 45 (10 pmol) 
LongAmp DNA Polymerase (NEB, MA, USA) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  64°C for 30 sec 
5. Elongation  72°C for 2 min 
6. Repeat   step 3. to 5. 18 times with reduction of annealing  
     temperature for 1°C every cycle 
7. Denaturing  94°C for 30 sec 
8. Annealing  45°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. – 9. 17 times 
11. Elongation  72°C for 7 min 
12. Storage  at 4°C 
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6.2.4 MCMV ie1/3 Exon1 loxP 
 
To amplify the ie1/3 Exon1 loxP construct from the plasmid send by Eurofin MWG 
Operon the following mix was used: 
 
50 µl in total: 
 
1 µl 
10 µl 
1 µl 
1 µl 
1 µl 
5 U 
Adjust to 50 µl 
4 ng Plasmid-DNA 
5x Puffer 
dNTPs (2,5 mM each dNTP) 
Primer 46 (10 pmol) 
Primer 47 (10 pmol) 
LongAmp DNA Polymerase (NEB, MA, USA) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  60°C for 30 sec 
5. Elongation  72°C for 1 min 
6. Repeat   step 3. to 5. 18 times with reduction of annealing  
     temperature for 1°C every cycle 
7. Denaturing  94°C for 30 sec 
8. Annealing  45°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. – 9. 25 times 
11. Elongation  72°C for 7 min 
12. Storage  at 4°C 
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6.3 PCR Mix and Programs to Detect Viral DNA 
 
6.3.1 MCMV ie3 pA loxP 
To amplify the ie3 pA loxP site from MCMV BAC or cell culture SN the following mix 
was used: 
 
25 µl in total: 
 
1 µl/0,5 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
SN/ MCMV BAC 
2x MangoMix (Bioline) 
Primer 18 (10 pmol) 
Primer 19 (10 pmol) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  60°C for 30 sec 
5. Elongation  72°C for 1 min 
6. Repeat   step 3. to 5. 18 times with reduction of annealing  
     temperature for 1°C every cycle 
7. Denaturing  94°C for 30 sec 
8. Annealing  45°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. – 9. 25 times 
11. Elongation  72°C for 7 min 
12. Storage  at 4°C 
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6.3.2 MCMV ie1/3 Exon1 loxP 
To amplify the ie1/3 Exon1 loxP site from MCMV BAC or cell culture SN the following 
mix was used: 
 
25 µl in total: 
 
1 µl/0,5 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
SN/ MCMV BAC 
2x MangoMix (Bioline) 
Primer 46 (10 pmol) 
Primer 47 (10 pmol) 
H2O 
 
The following PCR program was used: as described above in MCMV ie3 pA loxP. 
 
6.3.3 MCMV ie1/3 knock-out 
To amplify the ie1/3 knock-out from cell culture SN the following mix was used: 
 
25 µl in total: 
 
1 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
SN 
2x MangoMix (Bioline) 
Primer 18 (10 pmol) 
Primer 47 (10 pmol) 
H2O 
 
The following PCR program was used: as described above in MCMV ie3 pA loxP. 
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6.4 PCR Mix and Programs to Genotype Transgenic Mice 
 
6.4.1 C57BL/6 R26Cre.ERT2 Part 1 
To check for presence of Cre.ERT2 (Primer are binding in the gene Cre.ERT2) the 
following mix was used: 
 
25 µl in total: 
 
1 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
Genomic DNA 
2x MangoMix (Bioline) 
Primer 20 (10 pmol) 
Primer 21 (10 pmol) 
H2O 
 
The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  67°C for 30 sec 
5. Elongation  72°C for 2 min 
6. Repeat   step 3. – 5. 35 times 
7. Elongation  72°C for 7 min 
8. Storage  at 4°C 
 
6.4.2 C57BL/6 R26Cre.ERT2 Part 2 
To check if mice were homozygous or heterozygous for the gene Cre.ERT2 (Primer 
binds in the wild type gene Rosa26) the following mix was used: 
 
25 µl in total: 
 
1 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
Genomic DNA 
2x MangoMix (Bioline) 
Primer 135 (10 pmol) 
Primer 136 (10 pmol) 
H2O 
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The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  61°C for 30 sec 
5. Elongation  72°C for 2 min 
6. Repeat   step 3. To 5. 15 times 
7. Denaturing  94°C for 30 sec 
8. Annealing  58°C for 30 sec 
9. Elongation  72°C for 2 min 
10. Repeat   step 7. to 9. 15 times 
11. Denaturing  94°C for 30 sec 
12. Annealing  55°C for 30 sec 
13. Elongation  72°C for 2 min 
14. Repeat   step 11. – 13. 15 times 
15. Elongation  72°C for 7 min 
16. Storage  at 4°C 
 
6.4.3 C57BL/6 Rag2floxxR26Cre.ERT2 Part 1 and 2 
To check for presence of Cre.ERT2 (Primer are binding in the gene Cre.ERT2) the 
following mix was used: as described above for C57BL/6 R26Cre.ERT2 Part 1 and 2 
 
6.4.4 C57BL/6 Rag2floxxR26Cre.ERT2 Part 3 
To check if mice were homozygous or heterozygous for the loxP sequences flanking 
the gene Rag2 the following mix was used: 
 
25 µl in total: 
 
1 µl 
12,5 µl 
1 µl 
1 µl 
Adjust to 25 µl 
Genomic DNA 
2x MangoMix (Bioline) 
Primer 102 (10 pmol) 
Primer 103 (10 pmol) 
H2O 
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The following PCR program was used: 
 
1. Lid   103°C 
2. Initial denaturing 94°C for 5 min 
3. Denaturing  94°C for 30 sec 
4. Annealing  55°C for 30 sec 
5. Elongation  72°C for 1 min 
6. Repeat   step 3. – 5. 35 times 
7. Elongation  72°C for 7 min 
8. Storage  at 4°C 
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